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Genome-wide association studies (GWAS) have become a a widely adopted ap-
proach to identify genetic variation that produces variation in complex pheno-
type. Standard statistical methods are able to identify strong associations in
these datasets, but more sophisticated statistical methods that model complex
aspects of the biological data can identify weaker associations and further eluci-
date the underlying molecular biology. We develop and apply statistical meth-
ods that explicitly model two aspects of GWAS data using two complementary
forms of regularized regression. First, we model the polygenic architecture of
complex phenotypes using feature selection methods in a penalized regression
framework. We propose novel algorithmic, computational and heuristic ap-
proaches in order to produce a method that scales to high dimensional GWAS
data and increases power to detect weak associations that are not detectable by
standard tests. Second, we model the covariance between individuals due to
kinship and population structure using a linear mixed model that regularizes
the statistical contribution of a metric of ancestry. Linear mixed models have
been widely adopted for analysis of GWAS data, but their theoretical proper-
ties have not been examined in this context. We formalize the statistical prop-
erties of the linear mixed model, develop a novel interpretation in relation to
population genetics, and propose a novel low rank linear mixed model that
learns the dimensionality of the correction for kinship and population structure
from the data. Finally, we combine these two complementary regularized re-
gression models into a penalized linear mixed model. We develop a unified
model incorporating a novel algorithm with novel approaches to tuning non-
convex penalties and determining the optimal stopping point in the regulariza-
tion path. Leveraging recent work on assessing significance of selected features,
we produce a well-principled and scalable statistical method applicable to fea-
ture selection, hypothesis testing and prediction in many contexts.
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CHAPTER 1
INTRODUCTION
1.1 Genome-Wide Association Studies
Understanding how genetic variation leads to variation in phenotype has long
been the goal of quantitative genetics. Establishing a link between genotype
and phenotype elucidates the molecular mechanisms underlying the pheno-
type and is a broad interest in medical, agricultural and model-organism genet-
ics. Genotyping technologies assaying over 1 million common single nucleotide
polymorphisms (SNPs) in humans has facilitated hundreds of genome-wide as-
sociation studies (GWAS) [68]. These studies have advanced the understand-
ing the molecular biology of common diseases [80, 88, 140, 164, 178, 193] as
well as drug response [229], metabolic [38, 179, 180, 185] and anthropomet-
ric phenotypes [95, 174]. This research has laid the foundation for new ap-
proaches to treatment by identifying genetic variants associated with drug re-
sponse [33, 76, 78, 135, 183, 228], characterizing current and potential drug tar-
gets [143, 194], and exploring the application of existing drugs to other diseases
[163].
1.1.1 Statistical methods model different aspects of biology
Standard analyses of GWAS datasets perform a separate test of association for
each genetic marker while including known confounding variables such as sex.
Single marker tests essentially consider the correlation between a single genetic
marker and a phenotype of interest. Such tests have been widely applied since
1
they are able to identify strong associations, they are scalable to very large
datasets, and they use a simple and interpretable statistical model. Yet these
methods do not model complexities of biological datasets and more sophisti-
cated methods have the potential to increase statistical power and decrease the
false discovery rate. To this end, much recent attention has focused on biological
complexities such as epistasis [21, 104, 119, 127, 133, 149, 159, 167, 191, 214, 223],
gene × environment interaction [6, 58, 116, 161, 186, 231], the effect of rare
variants [7, 98, 102, 120, 134, 151, 208, 220], gene- or pathway-based disease
models [21, 27, 73, 101, 105, 111], the polygenic architecture of complex traits
[9, 21, 65, 72, 114, 133, 227], and the confounding effect of kinship and popula-
tion structure [83, 84, 108, 109, 146, 150, 182, 230].
While there has been much work on each of these aspects of GWAS data, the
complexity and ever-increasing size of relevant datasets necessitates sophisti-
cated models grounded in biology that are still computationally scalable. The
complexities of the underlying biological system can be modeled by a range of
disparate approaches. Yet regularized regression stands out as being applica-
ble to each aspect discussed above [9, 27, 84, 208, 214, 231] and further being
able to incorporate prior biological knowledge [21, 118, 159]. Here, we apply
two complementary forms of regularized regression to modeling the polygenic
architecture of complex traits (Chapter 2) and correcting for kinship and popu-
lation structure (Chapter 3). Finally, we combine these methods into a unified
statistical method that models both of these aspects of GWAS data (Chapter 4).
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1.2 Regularized regression
In general, regularization introduces into a statistical model some prior knowl-
edge of the system underlying the observed data in order to avoid overfitting,
make the model computationally tractable, or explicitly conform to the prior. In
regularized regression, this takes the form of a prior on regression coefficients.
In the maximum likelihood context considered here, two complementary ap-
proaches to regularized regression take the form of a penalized regression and
a random effects model.
1.2.1 Penalized regression
In penalized regression, a prior is placed on the regression coefficients and the
corresponding penalized likelihood is maximized with respect to these coeffi-
cients, conditional on a fixed tuning parameter value. An illustrative example
is the so-called ridge regression [64, 70] of the form
LRidge(β|y) = N (y|Xβ, σ2e) N (β|0, λ) (1.1)
in which both the data likelihood and prior are Gaussian. In general, the data
likelihood and prior can be a chosen from number of distributions so that the
penalized log-likelihood can be expressed as a data log-likelihood term, and a
penalty (i.e. log prior) term
ℓpenalized(β|y) = ℓ(β|y)− pλ(β) (1.2)
indexed by a tuning parameter λ. There is an extensive literature concerning
how the choice of penalty affects the statistical properties of βˆ [5, 20, 41, 42, 67,
187].
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Table 1.1: Properties of feature selection penalties
Feature Tuning
Penalty selection Convex Oracle parameters Reference
Ridge no yes no 1 [70]
LASSO yes yes no 1 [187]
MCP yes no yes 2 [221]
LOG yes no yes 2 [124]
NEG yes no yes 2 [54]
Feature selection in penalized regression
In many applications of statistics the goal of an analysis is often to identify a
subset of features that are relevant to the response while discarding all other
features. Statistically, this is achieved by estimating the regression coefficients
of relevant features while setting the coefficients of irrelevant features to exactly
zero. This objective can be formulated in the context of penalized regression by
using a penalty that satisfies certain conditions and setting the tuning parame-
ter so that only a subset of the coefficients have nonzero coefficients. In order
to perform feature selection, the penalty function must be non-negative, non-
decreasing, and non-differentiable at the origin [42] (Figure 1.1, Table 1.1) . The
most widely used of such penalties is the LASSO (’least absolute shrinkage and
selection operator’) [187]. The fact the LASSO is convex means that it selects a
unique set of features with nonzero coefficients for a given value of the tuning
parameter when there are more samples (n) than features (p) [187, 189], and se-
lects a set of features that span a unique subspace when p > n [189].
Yet the convexity of the LASSO comes at a cost. For high-dimensional datasets,
4
Figure 1.1: Penalty functions used in penalized regression
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the LASSO is not guaranteed to recover the sparse structure of the true model
even asymptotically in the sample size [226]. However, other penalties satisfy
the so-called ‘oracle property’ whereby the coefficient estimates have the same
mean and covariance asymptotically as if the relevant features were known be-
forehand [42]. Such penalties have a derivative that approaches zero as the co-
efficient approaches infinity [42] and include MCP, LOG and NEG. Thus these
penalties have desirable statistical properties but practical and computational
issues arise due to the fact that they are are nonconvex and have two tuning
parameters. We address these issues to produce a scalable framework for non-
convex penalties that can outperform existing methods (Chapters 2 and 4).
1.2.2 Random effects models
In a random (or mixed) effects model, a prior is placed on the regression coeffi-
cients and the likelihood is maximized with respect to the variance components,
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while the coefficients are integrated out. An illustrative example is the standard
linear mixed model [145] of the form
LLMM(σ
2
a, σ
2
e |y) =
∫
N (y|Xβ, σ2e) N (β|0, σ2a) dβ (1.3)
where both the data likelihood and prior are Gaussian. This model is markedly
different from ridge regression due to the integral and the now essential role of
the variance components. Other forms of random effects models are possible
either by using a complementary data likelihood and prior distribution [100],
using numerical integration [50], or approximating the integral [77, 196, 206].
Widely used in applied statistics, random effects models allow fitting of overde-
termined systems, shrink coefficient estimates toward the prior mean and re-
duce the variance of estimates of fixed effects [145, 206]. In machine learning,
these models are termed Gaussian process regression (GPR) [157] and are ex-
pressed as
LGPR(σ
2
a, σ
2
e |y) =
∫
N (y|α, σ2e) N (α|0,Kσ2a) dα (1.4)
which is equivalent to (1.3) when K = XXT . GPR is thus a ‘kernel method’
where the kernel matrix, K, represents a metric of similarity between all pairs
of samples [157].
The linear mixed model has recently been widely adopted in statistical ge-
netics in order to account for the covariance between samples [83, 84, 108,
109, 146, 152, 182, 230] and many similarity metrics have been proposed
[8, 83, 96, 97, 144, 150, 165, 173, 215]. We formalize and interpret the relationship
between (1.3) and (1.4) in the context of statistical genetics and develop a novel
method that extends this framework (Chapters 3 and 4).
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CHAPTER 2
PUMA: A UNIFIED FRAMEWORK FOR PENALIZEDMULTIPLE
REGRESSION ANALYSIS OF GWAS DATA
2.1 Abstract
Penalized Multiple Regression (PMR) can be used to discover novel disease as-
sociations in GWAS datasets. In practice, proposed PMRmethods have not been
able to identify well-supported associations in GWAS that are undetectable by
standard association tests and thus these methods are not widely applied. Here,
we present a combined algorithmic and heuristic framework for PUMA (Pe-
nalized Unified Multiple-locus Association) analysis that solves the problems
of previously proposed methods including computational speed, poor perfor-
mance on genome-scale simulated data, and identification of too many associ-
ations for real data to be biologically plausible. The framework includes a new
minorize-maximization (MM) algorithm for generalized linear models (GLM)
combined with heuristic model selection and testing methods for identification
of robust associations. The PUMA framework implements the penalized max-
imum likelihood penalties previously proposed for GWAS analysis (i.e. Lasso,
Adaptive Lasso, NEG, MCP), as well as a penalty that has not been previ-
ously applied to GWAS (i.e. LOG). Using simulations that closely mirror real
GWAS data, we show that our framework has high performance and reliably
increases power to detect weak associations, while existing PMR methods can
perform worse than single marker testing in overall performance. To demon-
strate the empirical value of PUMA, we analyzed GWAS data for type 1 dia-
betes, Crohns’s disease, and rheumatoid arthritis, three autoimmune diseases
7
from the original Wellcome Trust Case Control Consortium. Our analysis repli-
cates known associations for these diseases and we discover novel etiologically
relevant susceptibility loci that are invisible to standard single marker tests, in-
cluding 6 novel associations implicating genes involved in pancreatic function,
insulin pathways and immune-cell function in type 1 diabetes; 3 novel asso-
ciations implicating genes in pro- and anti-inflammatory pathways in Crohn’s
disease; and 1 novel association implicating a gene involved in apoptosis path-
ways in rheumatoid arthritis. We provide software for applying our PUMA
analysis framework.
2.2 Introduction
Genome-wide association studies (GWAS) have identified many susceptibility
loci underlying the molecular etiology of complex diseases [68]. These stud-
ies have been responsible for the discovery of many individual genes that con-
tribute to disease risk [3, 10, 38, 46, 49, 95, 176, 195, 205], for discoveries on the
front line of personalized medicine [76, 228], and for discovering novel path-
ways important for the progression of complex heritable diseases [201]. The
expense of each GWAS that is capable of finding well-supported disease loci is
considerable and, as a consequence, each robust and interpretable association
discovered in a GWAS is valuable, not only from the point of view of scientific
discovery but also in terms of return on investment [4, 175]. A clear picture that
has an important bearing on the investment-discovery tradeoff in GWAS exper-
iments is that the associations identified to date generally explain only a small to
moderate fraction of total heritability [121, 122]. Recent analyses have suggested
that a considerable amount of this ‘missing’ heritability can be accounted for by
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rare variants or variants with weak effects [141, 215, 217]. This suggests that
there is an opportunity to identify more risk loci through studies that require
even greater investment, by including larger sample sizes and/or by incorpo-
rating higher genetic marker coverage of the genome by using next-generation
sequencing (NGS). The novel associations discovered by large consortia GWAS
studies support this supposition [3, 38, 49, 95]. Another complementary strategy
that leverages both the current and future investment in GWAS experiments is
the application of new statistical analyses that can reliably identify weaker asso-
ciations [72, 91, 127, 160, 200]. Although there has been an explosion of methods
in this area [21, 133], few have produced robustly supported associations that
are not detectable by single marker tests of association [21, 68, 133, 178, 193].
Here we report a general framework for applying a family of GWAS analysis
methods that is extremely promising for detection of weak associations yet has
not been widely applied to learn novel biology from GWAS datasets: penalized
multiple regression (PMR) methods. PMR methods work by simultaneously
incorporating tens to hundreds of thousands of genetic markers in a single sta-
tistical model where a penalty is incorporated to force most marker regression
coefficients to be exactly zero, so that only a small fraction are estimated tomake
a contribution to disease risk [9, 39, 57, 65, 72, 103, 114, 192, 209, 214, 227]. By
jointly analyzing markers, PMR methods are able to consider the correlation of
each marker with the phenotype, conditional on the effect of all other mark-
ers. This can increase the power to detect weak associations compared to single
marker methods due to the smaller residual variance and the fact that the condi-
tional correlation of a marker with the phenotype (i.e. the correlation of a given
marker with the phenotype once the estimated effect of all other relevant mark-
9
ers has been subtracted out) can often be substantially higher than the marginal
correlation [64]. The latter effect is a consequence of non-zero correlation struc-
ture between associated markers when the underlying genetic architecture is
polygenic [22]. These methods therefore model the underlying biology more
accurately than single marker tests, by explicitly modeling the polygenic archi-
tecture of complex phenotypes to account for the effects of multiple suscepti-
bility loci. They also leverage the same type of statistical model used in single
marker testing methods that have demonstrated reliability in the identification
of strong associations [68, 178, 193]. Yet, despite theoretical power of PMRmeth-
ods, the large body of statistical literature exploring their theoretical properties
(see reviews [20, 44]), and the recent interest in the methods development com-
munity [9, 39, 57, 65, 72, 103, 114, 192, 209, 214, 227], these methods have not
been successful in GWAS analysis. This is due to a combination of limitations:
1) inability to scale for very large GWAS datasets [9, 57, 72, 103], 2) poor per-
formance on simulated data [72, 209], 3) they often find too many ‘hits’ to be
biologically plausible for a given GWAS sample size [72], and 4) they do not
identify novel, well-supported associations that are not detectable by standard
methods [72, 209].
In order to address these issues, we present a combined algorithmic and heuris-
tic framework for PUMA (Penalized Unified Multiple-locus Association) anal-
ysis that optimizes these methods for reliable detection of weak associations
when applied to large GWAS datasets. The complete PUMA framework in-
cludes an extremely efficient implementation of a new minorize-maximization
(MM) algorithm [75] for generalized linear models (GLM) [125], a theoretically
motivated data-adaptive heuristic approach to determine penalty strength and
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for model selection, and post hoc methods for assessing the rank of identified
associations. Within PUMA, we implement all sparse feature selection, penal-
ized regression approaches proposed for GWAS analysis to date, including four
penalties implemented in a maximum likelihood framework (i.e. Lasso, Adap-
tive Lasso, NEG, MCP), as well as theoretically justified penalties that have not
been previously applied to GWAS (i.e. LOG) (Figure 2.1). We demonstrate the
power of our framework for detecting weaker associations that are invisible to
individual marker testing through analysis of simulated GWAS data that mir-
ror observations from analyses of real GWAS data. We also demonstrate that
our approaches correct issues with all current PMR methods where software is
available for GWAS analysis, where we find that all of these currently available
PMRGWASmethods can performworse than single marker testing for our sim-
ulation conditions. As an illustration of the value of PUMA for mining existing
GWAS data for novel associations, we apply these methods to the original Well-
come Trust Case Control Consortium (WTCCC) [205] GWAS datasets for type
1 diabetes, Crohn’s disease and rheumatoid arthritis. Our re-analysis identi-
fies weak associations that implicate additional susceptibility loci for these au-
toimmune diseases, which did not appear significant by standard single marker
tests of association in these datasets, yet were 1) identified in an independent
GWAS of the same phenotype that did not include WTCCC data, 2) previ-
ously known to play a role in disease etiology, or 3) known to function in a
relevant biological pathway. Our results demonstrate that appropriately tuned
PMR methods can provide a complementary approach to large meta-analyses
[3, 10, 38, 46, 49, 95, 176] to identify susceptibility loci with weak associations.
We also provide a discussion concerning how the framework can be extended
to perform penalized analysis of epistasis, to incorporate mixed model analy-
11
sis, and to address challenges of genome-wide genotypes provided by whole-
genome next-generation sequencing.
Figure 2.1: Penalty functions on the magnitude of the regression coeffi-
cients implemented in the PUMA framework. A parameter de-
termines the slope near the origin for all penalties, while MCP,
LOG and NEG have an additional tuning parameter determin-
ing the rate at which the derivative of the penalty tails off to
zero.
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2.3 Results
2.3.1 PUMA is a scalable framework for GWAS analysis
The methods implemented in our PUMA framework are orders of magnitude
faster than existing software when assigned identical computational tasks and
no pre-screening of markers is performed (Table 2.2). This substantial boost in
computational speed allows PUMA to perform a dense two-dimensional search
of tuning parameter values for non-convex penalties (i.e. MCP, NEG, LOG) and
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examine upwards of 1 million total modes of the likelihood surface for simu-
lated case/control dataset of 5,000 individuals and 650K genetic markers in less
than 24 hours on a 6 core Intel R© Xeon R© W3690 @ 3.47GHz with 12 Gb memory
when a pre-screening p-value cutoff of 0.01 from single marker analysis is ap-
plied (Table 2.1). This is a huge improvement compared to existing software for
non-convex PMR methods [9, 72] which only examine a single mode.
2.3.2 Theoretical and empirical justification for pre-screening
markers
While pre-screening markers based on a p-value cutoff may initially seem to de-
tract from the purpose of a multiple-locus analysis, it is supported by statistical
theory, is necessary for large scale analysis and has almost no impact on the set
of markers identified as associated. In a seminal paper, Fan and Lv [43] demon-
strate that pre-screening by ranking the marginal correlation of each variable
with the response will retain the relevant variable asymptotically with proba-
bility tending to 1. Fan and Song [44] extend this result to generalized linear
models. Moreover, Tibshirani, et al. [188] and El Ghaoui, et al. [52] establish ex-
act pre-screening methods for linear and logistic Lasso models where relevant
variables are guaranteed to be retained for finite sample sizes and demonstrate
that the number of variables can be reduced by up to 3 orders of magnitude. In-
tuitively, both the asymptotic [43, 44] and exact pre-screening methods [52, 188]
rely on the fact that a variable is unlikely to have a very small marginal corre-
lation with the response but a large and very significant conditional correlation
for a particular sample size when the relevant variables explain only a small
13
Table 2.1: Run times for PUMAmethods and other available software. For
a typical simulated data set with 5000 individuals, 650Kmarkers
and a pre-screening p-value threshold of 0.01, we report the run
times, and the number of total and unique models examined by
our methods (top) and available methods using standard / de-
fault settings (bottom). We list the number of models assessed
during a single run of a method where a model is defined by the
set of markers with distinct nonzero coefficients and the number
of unique models counts the number of sets of distinct markers,
where we note that the metrics reported can vary substantially
between datasets. Lasso and Adaptive Lasso are convex and
have a single tuning parameter, so relatively few models are ex-
amined during the search. For convex penalties, each distinct
tuning parameter value produces a model, although another
tuning parameter value can cause the coefficients to change but
still produce the same set of markers with nonzero coefficients.
Thus the number of models examined is larger than the num-
ber of unique models. MCP, LOG and NEG penalties are non-
convex and have two tuning parameters and were applied with
100 marker reorderings, so they produce orders of magnitude
more total and unique models. We note that 1D-MCP is faster
than 2D-MCP as the former fixes the value of one tuning pa-
rameter. We note that HyperLasso [72] can be extremely com-
putationally expensive for large datasets, so that the time we
report is based on analysis of the pre-screened dataset where
pre-screening step must be implemented separately. Ayers and
Cordell [9] do not provide software but proposes an approach
using the grpreg package in R.
Method Run time # of models # of unique models
Lasso 33 s 156 59
Adaptive Lasso 5 s 21 13
LOG 6 hrs ∼ 700, 000 ∼ 4, 000
NEG 5 hrs ∼ 500, 000 ∼ 10, 000
1D-MCP 21 min ∼ 800, 000 21
2D-MCP 14 hrs ∼ 1, 000, 000 ∼ 5, 000
Mendel [209] 66 s 1 1
HyperLasso [72] 1 hr 1 1
perm-MCP [9] 1 hr 1 1
fraction of the variation in the response. Moreover, pre-screening is often com-
putationally necessary because storing 650K markers for 5000 samples requires
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Table 2.2: Run times for PUMA and other available software for identical
analyses. For a typical simulated data set with 650K markers,
no pre-screening of markers and sample sizes, n, of 1000, 2000
and 5000, we report run times for available software and PUMA
performing the same analyses. For Lasso, we had Mendel and
PUMA perform a search of tuning parameter space in order
to return 1.5
√
n markers with nonzero coefficients. For NEG,
we set HyperLasso to its default tuning parameter values and
ran PUMA with the same values. For MCP, we set grpreg and
PUMA to perform a search of tuning parameter space in order to
return 1.5
√
nmarkers with nonzero coefficients, where γ was set
to 30 as per Ayers and Cordell [9]. Analysis was performed on
an 8 core Intel R© Xeon R© E5520 @ 2.27GHz with 32 Gb memory.
NA indicates the program crashed due to insufficient memory;
we note that this is due to technical limitations of Mendel and R,
in which grpreg runs.
Sample size
Method 1000 2000 5000
Lasso 2m 11s 5m 55s 14m 45s
NEG 1.2s 2.2s 9.8s
MCP 4.7s 8.2s 29.2s
Mendel [209] (Lasso) 9m 50s NA NA
HyperLasso [72] (NEG) 52m 24s 4h 16m 20h 3m
grpreg [9] (MCP) 3h 52m NA NA
26 Gb of memory. Finally, we note that pre-screening is used by previous appli-
cations of PMRmethods to GWAS data [72, 209] in order to handle genome-scale
data.
We use a pre-screening p-value cutoff based on single marker analysis, because
1) it retains all relevant variables asymptotically [43, 44], 2) it approximates the
exact methods proposed for Lasso [52, 188], which cannot be easily adapted to
other penalties, 3) it reduces memory requirements so that very large datasets
can be analyzed on a high-end desktop computer, 4) it substantially reduces
the computational burden, 5) by using a p-value it is naturally calibrated to the
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sample size and the fraction of variation in the response being explained, and 6)
it has very little empirical effect on the results.
We demonstrate this final andmost important point in two complementary sim-
ulation studies. First we consider a simple two-step forward regressionmethod,
which is known to approximate penalized multiple regression [37, 63] and, un-
der a range of biologically motivated simulation conditions, demonstrate that
variables that do not cross an initial p-value threshold have a very low probabil-
ity of being significant in the second step (Figure A.1). Second we demonstrate
that the pre-screening has no noticeable effect on the performance of Lasso and
MCP methods but substantially reduces the computational time (Figure A.2).
2.3.3 Simulated data assessment of the PUMA framework
We analyzed 960 simulated GWAS datasets to assess the performance of our
PUMA framework compared to other published methods for PMR GWAS anal-
ysis. We note that these simulations, while far more extensive than other pub-
lished works on PMRGWAS analysis [9, 39, 57, 65, 72, 103, 114, 209, 214, 227] are
not meant to be exhaustive or to capture all the possible complexities in a GWAS
but rather to: 1) serve as a baseline for comparing GWAS analysis methods and
2) provide an estimate of the expected performance for these methods when ap-
plied to GWAS data under relatively ideal experimental conditions. Our goal
therefore was not to attempt to model a broad spectrum of possible GWAS data
complexities (e.g. stratified experimental sampling schemes, known or cryp-
tic population structure effects on phenotype, relatedness among individuals,
measured or latent covariates, etc.) but rather to simulate data that captured
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the most basic components of a GWAS experiment (see Methods for details). In
simulated data a causal variant is defined as a variant whose coefficient value
is nonzero, so that number of minor alleles at this marker contributes to the
phenotype. In order to mimic the fact that true causal variants are not available
from array-based genotyping, the simulated causal variants were removed from
the dataset so that they are not considered by the tests of association. Therefore,
just like in all array-based genotyping datasets, our simulations identify asso-
ciations based on markers in linkage-disequilibrium with the (omitted) causal
variant.
2.3.4 Assessment of available software for PMR GWAS
We assessed the performance of PMR methods for which there is available
software. We compared the performance of the Lasso penalty from Wu, et
al. [209], the NEG penalty as implemented in the HyperLasso program [72],
and a permutation-based approach to selecting tuning parameter values for the
MCP penalty [9, 221] that we term perm-MCP. We note that we only consid-
ered PMR approaches that are designed to handle the specific challenges of
GWAS data and that also perform feature selection, such that we do not con-
sider ridge, elastic net, or group-penalties since they set many correlated mark-
ers to have nonzero coefficients and thus complicate the generation of inter-
pretable p-values [28, 227]. We also did not considerMarkov ChainMonte Carlo
(MCMC) approaches [57, 103] since they could not efficiently scale to genome-
wide data while exploring a range of tuning parameter values. We ran the Hy-
perLasso program [72] with standard settings (see Appendix A.2). We applied
the method ofWu, et al. [209], setting the number of selectedmarkers to the true
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number of causal markers in each simulation since Wu, et al. [209] do not spec-
ify a criterion for selecting the model size. As a benchmark, we also ran a single
marker analysis implemented by applying a logistic regression model to each
marker individually. We used a pre-screening p-value cutoff of 0.01 from single
marker analysis for the PMR methods to make them computationally tractable.
Simulations indicate that HyperLasso [72] and the Lasso of Wu, et al. [209]
are generally less powerful than a standard single marker test (Figure 2.2, A.3-
A.10). While Lasso is sometimes comparable or slightly more powerful than a
single marker test for low FDR, the performance of the method benefits from the
fact that the number of selected markers is set using information not available
in real data. Setting the marker number to 10 (the default in the implementation
of Wu, et al. [209]) or another arbitrary value results in poor performance and is
not competitive with a single marker test (results not shown). The performance
of HyperLasso is especially poor as is it suffers from the fact that the choice
of tuning parameters has a huge effect on performance, but the method does
not implement a search over tuning parameter values. Moreover, HyperLasso
does not include a way to evaluate the significance of a selected marker, so we
used their default approach of using coefficient values from selected markers
to assess performance. Alternatively, perm-MCP was the most powerful in our
simulations.
We note that for perm-MCP, by setting the expected false positive rate (eFPR)
and using permutations to obtain the value of the tuning parameter based on
this rate, perm-MCP generates a single model with relatively few nonzero coef-
ficients while explicitly addressing the multiple testing problem. Yet in practice
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Figure 2.2: Simulation results for existing methods. Shown here are repre-
sentative examples of simulation results for available software
including the HyperLasso program [72] (HLASSO), Lasso us-
ing the method of Wu, et al. [209] (LASSO WU) and perm-
MCP method [9]. Power is compared to a standard single
marker analysis (SMA). Results are shown for 20 replicate
datasets from simulations with 5000 individuals, 20 causal
markers affecting disease risk and a heritability of 50%. Note
that perm-MCP selected very few markers per simulation so
the false discovery rate did not exceed 10%.
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this result indicates that perm-MCP may assign p-values to only a handful of
markers so that the method may not identify any novel associations for a par-
ticular dataset. Since the number of nonzero coefficients is directly related to
the specified eFPR and the pre-screening cutoff, we examined multiple eFPR
values (1× 10−3,1× 10−4,1× 10−5,1× 10−6,1× 10−7) and cutoff values (0.1, 0.01,
0.001), and selected the values the yielded the highest power (eFPR=1× 10−3,
cutoff=0.001) to present in Figure 2, where other cutoff combinations produce
poorer performance (see Figure A.11 for a representative plot showing the re-
sults for all cutoffs). We note that the eFPR value is based on the number of
markers that pass the pre-screening cutoff, not the total number of markers.
Therefore the performance of perm-MCP is sensitive to the eFPR and cutoff val-
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ues, yet there is no clear method to optimally specify this value a priori. Fur-
thermore, determining the appropriate cutoff for a desired eFPR for correlated
high-dimensional data is the subject of current research [53], and its application
to permutationmethods for selecting a tuning parameter remains an open ques-
tion. We also note that the performance achieved with PUMAmethods does not
require the optimal determination of eFPR and pre-screening cutoffs.
In addition, we note that while Ayers and Cordell [9] have previously shown
that penalized regression methods can perform well on simulated data, the
datasets we address here are orders of magnitude larger. Ayers and Cordell
[9] conducted two simulation studies, one with 4000 markers and the other
with no more than 228. By considering such a small set of markers, which is
not the product of a pre-screening step, they were able to use standard R pack-
ages and apply a permutation method to select tuning parameters on the full
dataset. Moreover, the multiple testing problem is less severe in their analysis.
For the HyperLasso program, Ayers and Cordell [9] selected the tuning param-
eter as described by Hoggart, et al. [72]. However, using these settings for the
genome-scale datasets examined here caused the HyperLasso program to crash
(Appendix A.2) and so we use the default program settings. We note that the
program worked as expected for smaller datasets. It is unclear whether this
problem is an issue with the underlying algorithm or the specifics of the imple-
mentation. Thus the difference between the performance of methods in Ayers
and Cordell [9] and the current study is the scale of the data, the large multiple-
testing burden for genome-scale data and the necessity of a pre-screening step
for genome-scale data.
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PUMA’s statistical power is due to its data-adaptive properties. PUMA 1) per-
forms a two dimensional search of the tuning parameter space 2) selects the
number of nonzero coefficients based on both the fit to the data and the sam-
ple size, and 3) uses a heuristic methods to assess the significance of correlated
markers. Conversely, perm-MCP fixes one of the tuning parameters, does not
incorporate the sample size, and does not address the issues of testing the signif-
icance of correlated markers. Moreover, perm-MCP relies on setting the eFPR
despite problem of determining an appropriate value a priori for high dimen-
sional data.
2.3.5 The potential of the PMR GWAS framework as imple-
mented in PUMA
For the 960 simulated GWAS datasets we analyzed, almost all PMR GWAS ap-
proaches implemented in PUMA except NEG and adaptive Lasso outperformed
single marker analysis under simulation conditions with sufficient sample size
(Figure 2.3, Figures A.3-A.10). Quite critically, the performance is far greater
even when using a conservative control of FDR that is commonly employed
in GWAS studies. Moreover, the improvement of the PMR methods in PUMA
is most noticeable for causal variants with intermediate marginal heritability.
Overall, these simulations demonstrate that the advantage of PMR methods
over a single marker test increases with sample size, but decreases with the
number of susceptibility loci (Figure A.3-A.4).
While the penalized methods implemented in our PUMA framework consis-
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Figure 2.3: PUMA methods outperform other tests of association. Shown
here are representative examples of simulation results for sin-
glemarker analysis (SMA), 2-step conditional regression, a per-
mutation based tuning of MCP (perm-MCP), our approximate
Bayesian method (VBAY), and our PUMA methods (Lasso,
Adaptive Lasso, LOG, NEG, 1D-MCP, 2D-MCP). Results are
shown here for 20 replicate datasets from simulations with
5000 individuals, 20 causal markers affecting disease risk and
a heritability of 50%. a) The power of each method to recover
true associations at a fixed FDR of 5% shown as a function of
the marginal heritability of each causal marker. b) Precision-
Recall curve for the same simulations as in (a). Note that perm-
MCP selected very few markers per simulation so the FDR did
not exceed 10%. c) Power to recover true associations at an
FDR of 5% for a range of sample sizes.
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tently had higher power than single marker analysis as a function of FDR un-
der most simulation conditions, none of the penalties consistently stood out as
the most powerful. However, our PUMA framework, which includes a fast
novel algorithm for penalized maximum likelihood estimation in generalized
linear models, data-adaptive tuning of tuning parameters, heuristics for model
selection and novel method of assigning p-values (see Methods) increased the
power of PMR methods compared to current approaches using the same penal-
ties [72, 209]. We note that our implementation of the NEG penalty showed a
substantial increase in power over the HyperLasso program [72] and indicates
that our search over tuning parameter values and heuristic approach for model
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selection was successful. Moreover, our search of one or both tuning parameter
values for MCP (termed 1D-MCP and 2D-MCP, respectively) showed that our
approach to applying MCP (i.e. 2D-MCP) can be more powerful than that of
Ayers and Cordell [9]. The fact that our implementation of Lasso had higher
power than the version of Wu, et al. [209] confirms the usefulness of our data-
adaptive approach for selecting penalty strength and our novel method for as-
signing p-values. We also note that for comparison we applied a conditional re-
gression test and our previously published algorithm VBAY, a variational Bayes
approach for fitting a mixture prior penalty [114]. We found that perm-MCP
and VBAY had similar performance to our PMR methods and while the con-
ditional test of association was sometimes more powerful than single marker
analyses it was generally not as powerful as the PUMA PMR methods.
2.3.6 Summary of Wellcome Trust Case Control Consortium
(WTCCC) re-analysis
In our re-analysis of type 1 diabetes, Crohn’s disease and rheumatoid arthritis
datasets, we applied a single-marker analysis and all PMR analysis approaches
(Lasso, Adaptive Lasso, NEG, LOG, 1D-MCP, 2D-MCP, perm-MCP) using all
the recommended components of our framework. We included sex and the
first two principal components of the genotype matrix [150] as unpenalized co-
variates, applied a pre-screening cutoff of 0.01 on the p-values from the single
marker test, and ran 100 reorderings for the non-convex penalties. Quantile-
Quantile (QQ) plots of p-values from a standard single marker analysis indicate
that the effects of any remaining population structure is minimal. Moreover,
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including the subset of significantly associated markers identified by the PMR
methods as covariates in a single marker analysis of remaining markers does
not yield an inflation of the QQ plots and thus indicates that the PMR methods
are not overfitting the data (Figure A.12). We also note that due to the complex
LD around the MHC on chromosome 6, we included this region in our analysis,
but we omit this region from any post hoc analysis and discussion.
Our single-marker re-analysis of type 1 diabetes, Crohn’s disease and rheuma-
toid arthritis datasets reproduced the same associations as reported in the origi-
nal analysis (Figure A.13). Our PMR methods recapitulated almost all of the as-
sociations identified by single marker analysis, although there were differences
among the methods. The PUMA Lasso and Adaptive Lasso identified almost
no additional associations compared to single marker tests, and while LOG,
NEG and 1D-MCP identified more, almost all of the associations found by these
five methods (Lasso, Adaptive Lasso, LOG, NEG, 1D-MCP) were identified by
2D-MCP (Figure 2.4, A.14). We note that perm-MCP identified very few associ-
ations (12 overall, across the three diseases), all but one of which was identified
by a single marker test, and all were identified by 2D-MCP.We therefore discuss
the associations found by 2D-MCP, where we consider three categories of inter-
est (Table 2.3): those concordant with single marker tests, those that recapitulate
associations identified in external GWAS studies but not by single marker anal-
ysis of the WTCCC, and novel associations, of which many were deemed to be
biologically interpretable in terms of the current knowledge of disease etiology.
In the absence of functional validation, the presence of a feasible biological in-
terpretation lends more credibility to these novel findings.
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Table 2.3: Number of associations identified in the analysis of Wellcome
Trust Case Control Consortium (WTCCC) data by disease and
category. Number of associations identified for Crohn’s disease
(CD), rheumatoid arthritis (RA) and type 1 diabetes (T1D) di-
vided into 5 categories for the union of all associations identified
by PUMAmethods.
CD RA T1D
Concordant with SMA 8 1 4
Replications not significant by SMA
Independent datasets 0 0 1
Non-independent datasets 5 0 1
Etiologically relevant associations 3 1 6
Other novel associations 12 11 11
A critical point to note about the performance of our PUMA framework for PMR
analysis of GWAS data is that these methods not only result in the correct identi-
fication of more loci than a single marker testing analysis (when controlling the
false discovery rate at the same level), but also lead to re-orderings of the rank
of markers that are considered the most significant when compared to a single
marker analysis (Figure 2.5). As a consequence, we are able to identify etiolog-
ically relevant and replicated disease loci that are too weak to be detected by
single marker analysis, yet show strong signals of association by PMR analysis.
This means that our PMR GWAS analysis is not simply taking advantage of the
lower residual variance to improve performance, but is also taking advantage
of the fact that conditional correlation of a relevant marker with the phenotype
is often more significant than the marginal correlation. When the coefficients
for multiple markers, each tagging different susceptibility loci throughout the
genome, have nonzero values in the PMR framework, their association with
the phenotype becomes more significant. Our framework can therefore identify
disease susceptibility loci in a GWAS with weak associations with phenotype,
when they are invisible to a single marker testing approach (i.e. they have p-
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values in a single marker test that would never be considered significant).
2.3.7 Associations identified by PUMA are concordant with as-
sociations from single marker tests
The associations identified by PUMA generally recapitulate associations iden-
tified by single marker analysis, and the PUMA hits have perfect concordance
for strong associations. Overall 2D-MCP recapitulates the largest number of
associations, while the union of the other PMR methods (considered here for il-
lustrative purposes due to the high degree of concordance with each other, and
the fact that 2D-MCP identifies almost all of the associations they find) had a
lower degree of concordance with the single marker analysis (Figure 2.4, 2.6,
A.14, Table A.1). Of the 6 associations identified by a single marker analysis
that were missed by our methods, 5 were from type 1 diabetes and 1 was from
Crohn’s disease (Table A.2). One of these associations was borderline significant
by 2D-MCP with a p-value of 1.42× 10−7.
2.3.8 PUMAmethods replicate associations identified by exter-
nal studies
We compared associations identified by our PUMA methods that were not de-
tected by single marker tests in the WTCCC dataset to markers identified by in-
dependent studies in the HuGE database of published GWAS [218] in order to
find associations identified in both our analysis and an independent study that
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did not include WTCCC data. Such replications are considered the gold stan-
dard for validating a putative association [25]. In the ideal case the samemarker
would show an association in both the WTCCC dataset and those summarized
in the HuGE database. However, given 1) the lack of overlap of marker-sets be-
tween genotyping platforms, 2) that the HuGE database reports only the most
significant marker in an associated LD block, and 3) that PMR methods tend
to select only a single marker within a LD block, we considered a marker to
recapitulate a known association if the two are within 0.1 cM [10]. A representa-
tive example from Crohn’s disease is shown in Figure 2.7 where only 2D-MCP
is able to identify STAT3 as a susceptibility locus in the WTCCC dataset (Fig-
ure 2.7a). While this association has also been replicated in non-independent
datasets [10], which included WTCCC data, the role of STAT3 in Crohn’s and
other autoimmune disease is well established [24, 40].
While all PUMA methods and a single marker test are able to replicate associ-
ations from independent studies, LOG, NEG and 1D-MCP, stood out in terms
of identifying associations replicated by non-independent studies, but not de-
tected in the WTCCC dataset by a single marker analysis. These counts reflect
the results when the number of markers considered as ‘hits’ was set to be equal
across methods so that they reflect the ordering of markers by PMR methods
rather than the number of associations. When comparing the total number of
significant hits from each method to associations identified in either indepen-
dent studies or non-independent external studies that incorporated WTCCC
data, 2D-MCP is the only PMR method to identify as many total replicated
associations as a single marker test (Tables 2.5, A.3–A.4, Figures A.15–A.19).
However, 2D-MCP is able to replicate known associations that cannot be repli-
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cated by a standard single marker test in this dataset, thus demonstrating that
PMR methods can extract biologically relevant information that is overlooked
by standard analyses (Table A.5). These results demonstrate that PMR meth-
ods overall are able to identify replicated associations in this dataset that are
invisible to a standard single marker test. Moreover, our methods provide an
opportunity to replicate previously unreplicated associations by re-analyzing
existing GWAS datasets.
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Figure 2.4: PUMA identifies associations for Wellcome Trust Case Control
Consortium (WTCCC) data that are novel and that overlap hits
from previous GWAS. Genome-wide plot of associations iden-
tified by analyzing the WTCCC data for type 1 diabetes using
PUMA and single marker tests. Replications from indepen-
dent (not including WTCCC data) and non-independent (in-
cludingWTCCC data) GWAS of the same disease are indicated
with pink boxes and diamonds, respectively. For comparison,
markers identified using a single marker association analysis
are presented in black circles, where we note that these same
hits are all identified by PUMAmethods. Also for comparison,
we relaxed the Bonferroni threshold for single marker analysis
(open circles) until the same number of associations as found
by PUMA methods are reported, where we note that many of
these additional hits tend not to overlap PUMA hits or previ-
ous GWAS hits. Arrows indicate novel associations that are
biologically interpretable (see Table 2.6).
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Figure 2.5: Etiologically relevant and replicated genes identified by 2D-
MCP have non-significant p-values by standard single marker
analysis. Quantile-quantile (QQ) plot shows results from a sin-
gle marker analysis of type 1 diabetes from the WTCCC with a
subset of hits identified by 2D-MCP highlighted. P-values from
the single marker test are shown in black, while each orange
circle indicates a region identified as significant by 2D-MCP
and its location on the plot is determined by the most signifi-
cant single marker analysis p-value within 0.1 cM of the signif-
icant 2D-MCP hit. Biologically relevant genes identified by 2D-
MCP are shown with arrows indicating the most significant as-
sociation in the region by single marker analysis. Genes shown
on the left are only detectable with 2D-MCP, while genes on
right are identified by both 2D-MCP and single marker analy-
sis. P-values from the MHC region on chromosome 6 are omit-
ted.
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Figure 2.6: Venn diagrams showing concordance between methods.Venn
diagrams show the overall concordance between regions iden-
tified by a single marker test, 2D-MCP and the union of Lasso,
Adaptive Lasso, NEG, LOG, 1D-MCP and VBAY for Crohn’s
disease (CD), rheumatoid arthritis (RA) and type 1 diabetes
(T1D) for the WTCCC analysis. Areas are approximately pro-
portional to the counts shown and empty regions correspond
to a count of zero.
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Figure 2.7: Local manhattan plots illustrating individual examples of as-
sociations identified by PUMA analysis of the Wellcome Trust
Case Control Consortium (WTCCC) data. The top panel shows
− log10 p-values (left axis, all methods except VBAY) and pos-
terior probabilities for VBAY (right axis) for markers in the lo-
cal genomic region, gene models are shown below in orange
with the names of the associated gene indicated, the middle
panel shows recombination rates and genetic distance from
where the associated marker is indicated with an asterisk and
the bottom panel shows a linkage disequilibrium plot among
markers in the region using D′. a) A region identified only
by 2D-MCP replicates an association from a non-independent
studies (which included WTCCC data) of Crohn’s disease, b)
a novel association identified for type 1 diabetes only by a
PUMA method (2D-MCP) that implicates the etiologically rel-
evant SLC30A1 gene, and c) an association identified only by
a PUMAmethod (2D-MCP) for type 1 diabetes that implicated
the LPHN2, a gene previously identified but not replicated as
a risk locus for type 1 diabetes. Although the associations from
the independent studies do not tag the same linkage disequi-
librium block as the association identified by 2D-MCP, all three
likely affect LPHN2 as they are located either in or directly up-
stream of this gene and next closest gene is 1.8 Mb (1.7 cM)
away.
v
b
a
y
p
o
s
te
ri
o
r
p
ro
b
a
b
ili
ty
c
M
/
M
b
T1D hit region, chromosome 1
( rs613232 )  
0
5
10
15
0
0.2
0.4
0.6
0.8
1
genes
0
30
60
0
1
2
211.5 211.6 211.7 211.8 211.9 212.0
*
*
Single marker test
Conditional test
VBAY
Lasso
Adaptive Lasso
2D-MCP
LOG
NEG
Independent hit
Non−independent hit
T1D hit region, chromosome 1
( rs9324178 )
0
5
10
15
0
0.2
0.4
0.6
0.8
1
genes
	

0
30
60
0
1
2
81.5 82.0 82.5 83.0
*
*
 	
   
 	
  
	

 	
  
CD hit region, chromosome 17
( rs744166 )
−
lo
g
1
0
(P
)
0
5
10
15
0
0.2
0.4
0.6
0.8
1
genes
0
30
60
0
1
2
c
M
fr
o
m
h
it
40.2 40.4 40.6 40.8
*
*


32
T
ab
le
2.
4:
N
o
v
el
et
io
lo
g
ic
al
ly
re
le
v
an
t
su
sc
ep
ti
b
il
it
y
lo
ci
id
en
ti
fi
ed
in
W
el
lc
o
m
e
T
ru
st
C
as
e
C
o
n
tr
o
l
C
o
n
so
rt
iu
m
(W
T
C
C
C
)
b
y
P
U
M
A
m
et
h
o
d
s.
G
en
es
w
er
e
d
ee
m
ed
to
b
e
et
io
lo
g
ic
al
ly
re
le
v
an
t
if
th
ey
h
av
e
b
ee
n
p
re
v
io
u
sl
y
as
so
ci
at
ed
w
it
h
et
io
lo
g
ic
al
ly
re
la
te
d
d
is
-
ea
se
s
o
r
ar
e
k
n
o
w
n
to
fu
n
ct
io
n
in
b
io
lo
g
ic
al
ly
re
le
v
an
t
p
at
h
w
ay
s
b
as
ed
o
n
p
u
b
li
c
d
at
ab
as
es
an
d
d
is
ea
se
li
te
ra
tu
re
.
T
h
e
si
g
n
ifi
-
ca
n
ce
o
f
m
ar
k
er
s
w
it
h
re
g
re
ss
io
n
co
ef
fi
ci
en
t
o
f
ex
ac
tl
y
ze
ro
b
y
a
p
en
al
iz
ed
m
ax
im
u
m
li
k
el
ih
o
o
d
m
et
h
o
d
co
u
ld
n
o
t
b
e
as
se
ss
ed
an
d
ar
e
in
d
ic
at
ed
w
it
h
a
d
as
h
.
M
et
h
o
d
d
is
ea
se
S
N
P
ch
ro
m
o
so
m
e
p
o
si
ti
o
n
S
in
g
le
m
ar
k
er
an
al
y
si
s
C
o
n
d
it
io
n
al
te
st
V
B
A
Y
L
as
so
A
d
ap
ti
v
e
L
as
so
L
O
G
N
E
G
1D
-M
C
P
2D
-M
C
P
p
er
m
-M
C
P
re
le
v
an
t
g
en
es
C
D
rs
90
32
28
2p
16
.2
53
,6
92
,0
48
1.
71
×
10
−
0
5
1.
71
×
10
−
0
5
0.
97
6
1.
79
×
10
−
0
6
1.
45
×
10
−
0
6
4.
99
×
10
−
0
7
-
7.
38
×
10
−
0
6
8.
01
×
10
−
0
9
2.
58
×
10
−
0
6
A
S
B
3
C
D
rs
11
62
75
13
14
q
32
.2
97
,5
39
,1
70
2.
27
×
10
−
0
5
1.
25
×
10
−
0
5
0.
98
3
9.
09
×
10
−
0
6
1.
07
×
10
−
0
5
5.
61
×
10
−
0
6
3.
02
×
10
−
0
5
2.
47
×
10
−
0
6
1.
06
×
10
−
0
9
-
V
R
K
1
C
D
rs
74
97
03
6
15
q
24
.1
74
,8
73
,6
78
1.
56
×
10
−
0
4
4.
3
×
10
−
0
5
0.
62
1.
19
×
10
−
0
6
1.
39
×
10
−
0
6
1.
94
×
10
−
0
6
6.
38
×
10
−
0
7
1.
73
×
10
−
0
6
6.
82
×
10
−
0
7
-
C
Y
P
11
A
1,
S
E
M
A
7A
R
A
rs
12
02
70
41
1p
36
.3
2
3,
59
1,
44
7
7.
55
×
10
−
0
6
7.
55
×
10
−
0
6
0.
03
83
1.
03
×
10
−
0
4
2.
83
×
10
−
0
4
4.
04
×
10
−
0
5
-
7.
4
×
10
−
0
5
7.
92
×
10
−
0
8
-
T
P
73
T
1D
rs
61
32
32
1q
32
.3
21
1,
76
9,
89
2
6.
51
×
10
−
0
2
1.
71
×
10
−
0
3
-
-
-
-
-
-
6.
96
×
10
−
0
8
-
S
L
C
30
A
1
T
1D
rs
40
74
41
5
3p
22
.3
33
,1
61
,7
44
7.
68
×
10
−
0
2
2.
17
×
10
−
0
3
-
-
-
1.
68
×
10
−
0
8
-
-
4.
45
×
10
−
0
8
-
C
C
R
4
T
1D
rs
41
50
24
5p
15
.3
1
9,
39
2,
35
7
1.
69
×
10
−
0
4
1.
03
×
10
−
0
4
0.
03
64
2.
37
×
10
−
0
5
1.
76
×
10
−
0
5
2.
1
×
10
−
0
5
-
5.
83
×
10
−
0
6
2.
59
×
10
−
0
9
-
S
E
M
A
5A
T
1D
rs
95
76
91
1
13
q
13
.1
32
,3
29
,1
17
1.
4
×
10
−
0
3
1.
27
×
10
−
0
6
0.
10
3
9.
75
×
10
−
0
8
3.
22
×
10
−
0
8
6.
85
×
10
−
0
7
-
4.
57
×
10
−
0
6
9.
45
×
10
−
0
8
-
R
X
F
P
2
T
1D
rs
71
57
29
6
14
q
21
.3
50
,5
66
,8
81
3.
59
×
10
−
0
5
1.
88
×
10
−
0
7
0.
90
6
3.
99
×
10
−
0
7
6.
79
×
10
−
0
7
1.
67
×
10
−
0
7
-
7.
72
×
10
−
0
7
3.
88
×
10
−
1
0
-
S
O
S
2
T
1D
rs
28
36
63
1
21
q
22
.2
40
,0
65
,9
05
9.
38
×
10
−
0
3
4.
78
×
10
−
0
4
-
-
-
4.
9
×
10
−
0
5
-
-
1.
08
×
10
−
0
8
-
E
R
G
33
Table 2.5: Number of associations identified in re-analysis of WTCCC
datasets that replicate associations from either independent or
non-independent GWAS. A study is considered to be indepen-
dent if it does not incorporate data from the WTCCC. An asso-
ciated marker is considered to replicate a known susceptibility
locus if it is within 0.1 cM a marker [10] reported as an associ-
ation for the same phenotype in the HuGE database. Numbers
in parentheses indicate the number of hits that are distinct from
those found by the single marker test.
Independent studies
Methods
disease SMA VBAY SMA Lasso Adaptive Lasso LOG NEG 1D-MCP 2D-MCP
CD 6 4 (0) 6 5 (0) 4 (0) 5 (0) 5 (0) 5 (0) 5 (0)
RA 1 1 (0) 1 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
T1D 4 2 (0) 4 2 (0) 3 (1) 3 (1) 0 (0) 3 (1) 2 (0)
Total 11 7 (0) 11 8 (0) 8 (1) 9 (1) 6 (0) 9 (1) 8 (0)
Non-independent studies
Methods
disease SMA VBAY SMA Lasso Adaptive Lasso LOG NEG 1D-MCP 2D-MCP
CD 3 4 (1) 3 2 (0) 2 (0) 2 (1) 5 (3) 3 (2) 6 (3)
RA 0 0 (0) 0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
T1D 2 0 (0) 2 0 (0) 1 (0) 1 (0) 0 (0) 1 (0) 2 (1)
Total 5 4 (1) 5 2 (0) 3 (0) 3 (1) 5 (3) 4 (2) 8 (4)
Grand total 16 11 (1) 16 10 (0) 11 (1) 12 (2) 11 (3) 13 (2) 16 (4)
2.3.9 PUMAmethods identify novel associations
Re-analysis of type 1 diabetes, Crohn’s disease and rheumatoid arthritis
datasets from the original WTCCC [205] with our PUMA methods revealed
novel associations that have not been identified in previous GWAS of these dis-
eases (Table 2.4, Figures A.14, A.20–A.22). These methods, most notably 2D-
MCP, identify novel associations in or near genes which have been previously
associated with etiologically related diseases or which are known to function in
biologically relevant pathways based on public databases and disease literature
(Tables 2.4,2.6). In addition, PUMA also identified associations without a clear
biological link to the disease phenotype (Tables A.6–A.8).
34
PUMAmethods identified novel susceptibility loci for type 1 diabetes involved
in pancreatic function, insulin pathways and immune cell function and for
Crohn’s disease that are involved in pro- and anti-inflammatory pathways (Ta-
ble 2.6). 2D-MCP identified a gene functioning in apoptosis as a susceptibility
locus for rheumatoid arthritis (Table 2.6). These genes are known to function
in relevant pathways or have been previously implicated in the etiology of the
disease but have not been found by previous GWAS of each disease. A rep-
resentative example is shown in Figure 2.7b where only 2D-MCP identifies an
association that implicates SLC30A1. This gene is a zinc transporter related
to SLC30A8, which has been implicated in type 2 diabetes, and zinc transport
plays a role in insulin secretion by pancreatic β-cells [86, 107].
2.4 Discussion
Each GWAS discovery that has a well supported association produces valuable
information for understanding the etiology of the disease phenotype and such
discoveries are regularly used as the foundation for studies that use the locus
as a starting point [69, 140]. Given that GWAS involving a thousand to sev-
eral thousands of individuals seldom return more than a few to a dozen well-
supported associations (depending on the disease) the monetary, time, and re-
source investment in these studies often translates to a considerable expendi-
ture per discovery. This is true even when considering additional discoveries
that may occur as individual GWAS are combined together into large meta-
analysis studies [3, 10, 38, 46, 49, 95, 176]. We have demonstrated that our
PUMA framework has the potential to produce added investment return for
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Table 2.6: Novel susceptibility loci identified by PUMAmethods and their
biological link to the disease. Genes were deemed to be etio-
logically relevant if they have been previously associated with
etiologically related diseases or are known to function in biolog-
ically relevant pathways based on public databases and disease
literature.
disease gene description
CD ASB3 functions in ubiquitination and degradation of TNF-R2,
which mediates TNF-α pro-inflammatory response [29,
212]
CD VRK1 phosphorylates c-Jun and p53, which both function in in-
flammation [171]
CD CYP11A1 cytochrome P450 enzyme that synthesizes anti-
inflammatory corticosterone in the intestine, and the
enzyme is underexpressed in inflamed colon biopsies of
patients with Crohn’s disease [31, 137]
CD SEMA7A immune semaphorin whose expression on activated T-cells
induces macrophage production of pro-inflammatory cy-
tokines [181]
RA TP73 p53-like transcription factors that functions in apoptosis, a
process implicated in the etiology of rheumatoid arthritis
[110, 213]
T1D SLC30A1 zinc transporter related to SLC30A8, which has been impli-
cated in type 2 diabetes, and zinc transport plays a role in
insulin secretion by pancreatic β-cells [86, 107]
T1D CCR4 chemokine receptor and CCR4-bearing T-cells function in
the autoimmune inflammation of the pancreas in mice [89].
A nearbymarker shows a strong association with celiac dis-
ease [36]
T1D SEMA5A member of the semaphorin protein family whose members
play a role in cell-cell interactions in immune processes, but
the function of this gene is not well characterized [181]
T1D RXFP2 receptor for relaxin, a member of the insulin protein family
[61]
T1D SOS2 Ras-guanine nucleotide exchange factor which is upstream
of a number of relevant signalling pathways [132]
T1D ERG ETS-family transcription factor that functions in pancreatic
development [90]
GWAS studies by discovering additional well-supported disease loci associa-
tions that are invisible to the standard single marker analysis methods responsi-
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ble for almost all reported GWAS [68, 218]. For example, our re-analysis of type
1 diabetes, Crohn’s disease and rheumatoid arthritis from the original Wellcome
Trust Case Control Consortium (WTCCC)[205] demonstrates that PUMAmeth-
ods can identify associations that are not detectable by single marker analysis
approaches but which replicate associations known from independent studies,
which did not include WTCCC data, as well as novel loci with strong links to
known disease etiology. These included 10 novel associations identifying genes
that are linked to primary pathways of these autoimmune diseases, specifi-
cally 6 genes involved in pancreatic function, insulin pathways and immune-
cell function in type 1 diabetes; 4 genes (in 3 association regions) functioning in
pro- and anti-inflammatory pathways in Crohn’s disease; and 1 gene involved
in apoptosis pathways in rheumatoid arthritis. Applying our PUMA frame-
work therefore has the potential to add a significant number of discoveries for
a given GWAS.
A critical property of our PUMA framework is it does not return the same or-
dering of significant markers produced by a standard single marker analysis.
By simultaneously accounting for the associations of multiple loci and better re-
flecting the underlying polygenic architecture of complex phenotypes, PUMA
can find strong statistical support for associations deemed non-significant by a
single marker analysis and places these among the top list of associations. A
prime example is marker rs613232 which had a p-value of 6.51× 10−2 by a sin-
gle marker analysis in the type 1 diabetes dataset so it would not be considered
for a follow-up study. However, by taking into account the polygenic architec-
ture of the trait, 2D-MCP assigned it a p-value of 6.96× 10−8 (Figure 2.7b, Table
2.4). This marker tags the zinc transporter SLC30A1 and zinc transport has an
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established role in type 1 diabetes, yet this gene was only identified as a suscep-
tibility locus by 2D-MCP. This example illustrates the power of PUMAmethods
to reorder the p-values of markers so that a marker that is not in the top 20,000
by a single marker test can be in the top 30 by 2D-MCP. Another example is that
of LPHN2, a gene identified by an independent GWAS of type 1 diabetes, yet the
association was not replicated in an independent dataset in the same study [59]
or, to our knowledge, any subsequent study. In our re-analysis, 2D-MCP identi-
fied a strong signal in a nearby marker and assigned it a p-value of 3.99× 10−9,
while the p-value by a single marker test was 3.78× 10−2 (Figure 2.7c, Table 2.4).
The very weak single marker p-value found in this dataset makes the previous
inability to replicate this association unsurprising. The gene encodes the G-
coupled protein receptor latrophilin 2 and has a weak association with rheuma-
toid arthritis [81] but its relation to disease etiology is unclear. These examples
illustrate that our PUMA framework returns additional and complimentary in-
formation to the results of a single marker analysis of a GWAS. In general, it
seems clear that applying a spectrum of appropriate GWAS analysis methods
to the same data is likely to maximize discovery.
The PUMA framework and software that we present here is immediately ap-
plicable to a large number of existing GWAS and we are currently exploring
extensions of the framework to address additional challenges in GWAS exper-
imental designs and GWAS analysis. For example, GWAS discoveries are reg-
ularly being produced by consortia that combine several independently exe-
cuted GWAS experiments. Such combined data introduce a number of com-
plexities including complex batch effects, population structure, relatedness, and
latent environmental variables. While meta-analysis techniques for combining
38
p-values across studies are a good approach to normalizing for many of these
issues [3, 10, 38, 46, 49, 95, 176], a PMR analysis directly on the genotypes can
include correction for study heterogeneity, population structure and cryptic re-
latedness using a linear mixedmodel [108, 169, 170], and we are currently work-
ing on such extensions. Given that the increase in performance for our PMR
methods compared to single marker analysis increases with increasing sample
sizes, solving these problems has great potential to detect additional weak as-
sociations. There is also going to be a near-term shift towards GWAS that add
millions of additional genetic markers genotyped by next-generation sequenc-
ing, which can add increased density of markers and different allele types. Our
approach can already handle these large number of markers directly to take ad-
vantage of the better tagging, and in some cases genotyping, of causal disease
polymorphisms. The trend of increased sample sizes and genomemarker cover-
age in GWAS also opens the opportunity to identify genetic interactions that are
currently difficult to detect, including epistasis and gene×environment inter-
actions, which could be identified by incorporating group penalty approaches
[129, 219, 227] within our framework. Overall, our framework represents a plat-
form for integrating richer statistical models and techniques for addressing the
future needs of GWAS.
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2.5 Methods
2.5.1 The PUMA framework
Our framework is a combination of algorithms and heuristic approaches de-
signed for robust and efficient analysis of GWAS datasets when the desired out-
put is a ranked list of genetic markers that individually tag disease loci. The
value of the framework is that tag genetic markers, which are too weak to be re-
liably identified by a single marker analysis, can be identified while preserving
a conservative FDR genome-wide. To solve issues that have limited the value of
existing PMR GWAS software for this purpose, we designed our framework to
have the following properties: 1) the versatility to handle a diversity of penal-
ties for simultaneous analysis of thousands to millions of genetic markers while
incorporating unpenalized covariates, 2) the efficiency to analyze up to millions
of markers after pre-screening on a standard desktop, 3) the sensitivity to tune
the strength of penalties and to perform model selection when the fraction of
variation accounted for by disease loci identifiable with tag markers is small
(as is typical for GWAS), and 4) the capability to return a ranked list of p-values
where each of the topmarkers identifies an independent disease association. We
outline the components of our framework responsible for each of these proper-
ties in the next four sections, followed by a description of our software PUMA
that implements our recommended practices and options for implementation.
We note that in its entirety, this framework is a new GWAS analysis approach
that incorporates novel components including (but not limited to): application
of penalties not previously applied to GWAS, a new MM algorithm for GLMs,
heuristics for penalty strength and model selection, and post hoc model fitting
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approaches for ranking associated markers.
2.5.2 Objective functions and penalties
Our framework makes use of a generalized linear modeling (GLM) framework
to construct the likelihood objective function. We can therefore model pheno-
types measured on a large diversity of scales by implementing an appropriate
link function [125], although here, we limit our implementations to an identity
and logistic link function to model continuous phenotypes with normal error
and case-control phenotypes, respectively. We also note that incorporating un-
penalized covariates is straightforward, where these are modeled with regres-
sion coefficients with no penalty. While our current implementation is restricted
to penalties that select a small number of well supported markers (i.e. feature
selection penalties [42, 56, 124, 187, 221, 232]), the framework is versatile enough
to implement a wide diversity of penalties approaches when making use of the
algorithm described in the next section.
For marker selection, we use the penalized maximum likelihood estimate
(pMLE) of the regression coefficients:
βˆ = argmax
β
ℓ(y|β)−
∑
j
pθ(βj) (2.1)
where y is the vector of disease phenotype values, and β is the vector of re-
gression coefficients ℓ(.) is the log-likelihood of a linear or logistic regression
and pθ(.) is the penalty function on the magnitude of βj indexed by a vector
of tuning parameters, θ. Since we are interested in identifying a small set of
variables associated with the phenotype, the penalty function must have the
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sparsity property whereby most of the regression coefficients are set to exactly
zero. Multiple penalties satisfy this condition while balancing computational
tractability with desirable theoretical properties. We implement the penalties
that have been applied for PMR GWAS analysis (i.e. Lasso, Adaptive Lasso,
NEG, MCP) as well as a penalty that has not be previously applied to GWAS
(i.e. LOG). We describe the properties of each penalty in the following para-
graphs and the functional form of each penalty is given in Appendix A.1.
The Lasso penalty [187] (previously implemented for PMR GWAS in the soft-
ware Mendel [209]) is a linear function of the magnitude of the regression co-
efficients and is the most widely used since it has a single tuning parameter.
Moreover, the penalty is convex so that it yields a unique pMLE. Yet it is widely
known to select too many variables with non-zero coefficients in high dimen-
sional datasets [42] and does not satisfy the “oracle property” whereby param-
eter estimates are asymptotically equivalent to unpenalized estimates when the
identity of the non-zero coefficients are known in advance [42].
The Adaptive Lasso penalty [232], (previously implemented for PMR GWAS
by Yang, et al. [214]) unlike the Lasso, satisfies the oracle property. This two-
step Lasso regression procedure is also convex (yields a unique pMLE) although
it requires an initial estimate of the regression coefficients, which are then used
to weight the strength of a Lasso penalty in the second step. There is no crite-
rion for determining optimal weights, so in practice the Lasso penalty for each
coefficient is weighted by the square root of the initial coefficient estimate.
The NEG penalty [56] (previously implemented for PMR GWAS in the soft-
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ware HyperLasso [72]) has two tuning parameters and is non-convex such that
it produces a multimodal likelihood surface where pMLE’s are not unique. The
penalty satisfies the oracle property, since the derivative of the penalties ap-
proach zero in the limit [42], although it has other less desirable properties since
its derivative approaches zero much more slowly than the other penalties and
its very complex functional form makes it numerically unstable for large coeffi-
cient values. In our framework, we re-implement NEG using a faster algorithm
than Hoggart et al. [72] and includes a two dimensional search of the tuning
parameter space, while [72] use asymptotic theory to set the tuning parameters.
The MCP penalty [221] (previously implemented in the R package grpreg [15])
has two tuning parameters. Like NEG, this penalty is non-convex and satisfies
the oracle property. However, the derivative of MCP reaches zero for finite co-
efficient values so that it avoids over penalizing large coefficient values. More-
over, MCP is designed to reduce the multimodality of the objective function
[221]. The tuning parameters determine the slope of the penalty near the origin
(i.e. λ) and coefficient value at which the derivative of the penalty is set to zero
(i.e. a or γ, depending on notation). When applying this method to GWAS data,
Ayers and Cordell [9] fixed the value of a at 30, and identify the value of λ using
a permutation approach. We term this approach perm-MCP. In addition, we
consider a one dimensional search over the value of λ and a two dimensional
search over both parameters, termed 1D-MCP and 2D-MCP, respectively. The
latter has the most potential since it explores the value of the tuning parameter,
a, that determines the coefficient value at which the derivative of the penalty is
set to zero, and learns the value of the parameter based on the data.
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We also implement the LOG penalty and apply it to GWAS for the first time.
The LOG penalty [124] has two tuning parameters and is non-convex, such that
it produces a multimodal likelihood surface where pMLE’s are not unique, but
is satisfies the oracle property, since the derivatives of the penalties approach
zero in the limit [42]. This penalty is also designed to identify fewer non-zero
regression coefficients.
2.5.3 Minorize-Maximization (MM) algorithm and scalable im-
plementation
Our framework implements a highly efficient algorithm and optimized cod-
ing practices to allow fast simultaneous analysis of genetic markers in the
range of hundreds of thousands to millions. We implement a new minorize-
maximization (MM) algorithm for finding pMLE by using a coordinate-wise
ascent approach with an upper bound on the second derivative of the likeli-
hood function [75]. By using bounded univariate updates, the algorithm is ex-
tremely fast and is guaranteed to converge to a mode of the likelihood surface.
While Newton-Raphson algorithms must evaluate the log-likelihood after each
update to check if it has decreased [14], the use of an MM algorithm for lo-
gistic regression guarantees a monotonic increase and eliminates the expensive
function evaluation. Derivations are given in Appendix A.1 . In addition to
the algorithm, we also implement a number of optimized coding practices to
accelerates these PMR methods. These include data structures to minimize ac-
cess time to each marker, use of optimized linear algebra libraries and searching
multiple modes of the likelihood surface for non-convex penalties in parallel.
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2.5.4 Adaptive tuning of penalties and model selection
Critical to the performance of our framework is preserving a conservative con-
trol of the FDR for identified markers. To accomplish this, we employ a strategy
that allows our PMR methods to automatically adapt, not only to the sample
size of the dataset, but also to the number and magnitude of the non-zero re-
gression coefficients for relevant markers associated with the phenotype. Our
approach includes an adaptive tuning of penalty strength in combination with
model selection and assessment of model fit.
Statistical theory considering linear regression has shown that for a sample size
of n, the number of variables detectable as having nonzero coefficients is on the
order of
√
n [222]. This is consistent with other theoretical work [74, 148] and
satisfies our intuition that the number of detectable associations is directly re-
lated to the sample size of the dataset. For adaptive tuning of the Lasso and
Adaptive Lasso, where the likelihood is convex and there is a single tuning
parameter, the search is simple and we start with a severe penalty, which is
gradually decreased to select one additional non-zero coefficient at a time, until
1.5
√
n genetic markers are selected. For the non-convex penalties [9, 72, 124],
a grid search over a two-dimensional space of tuning parameters is used start-
ing from equally spaced Lasso models (a special case of all non-convex penal-
ties) where the non-convexity of the penalty is gradually increased until 1.5
√
n
markers are selected. This approach for searching the space has been shown
to avoid some suboptimal modes of the likelihood surface [124]. We note that
we have previously published the approximate Bayesian methods, VBAY and
VBAYNET, which incorporate a probabilistic bound, wherewe applied the same
1.5
√
n bound [114, 115]. In order to mitigate the problem of suboptimal modes
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at least to some degree, we explore multiple modes of the likelihood surface
for non-convex penalties by permuting the order in which the regression coeffi-
cients are updated. For both the simulations andWTCCC analyses of this study,
we found 100 reorderings was sufficient to obtain robust results.
Once sets of markers with nonzero coefficients are identified for each value of
the tuning parameters for a given penalty, the optimal set is determined. We
assessed the overall appropriateness of the fit of a selected model based on a
QQ plot by fitting an unpenalized model with selected markers, and calculat-
ing p-values for each marker in the dataset by regressing it against the residuals
from the first step (Figure A.12) [113].
2.5.5 Post hoc assessment of p-value ranks
Themost valuable final output of a PMRGWAS analysis is a ranked list of mark-
ers in decreasing order of highest confidence. Standard methods for producing
such ranked lists in a PMR framework assess significance by conducting vari-
able selection on a subset of the data and assessing significance on another sub-
set [131], or subsetting the data many times and identifying variables selected in
many of the subsets [130]. Such methods can be very computationally demand-
ing for large GWAS datasets and have been shown to underperform a standard
single marker test of association [2]. Moreover, these methods do not address
the challenging problem of assessing the significance of a marker in the pres-
ence of correlated markers within the same linkage disequilibrium (LD) block.
While PMR methods tend to select a single non-zero regression coefficient for
an associated LD block, cases often arise where multiple markers in a LD block
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have non-zero coefficients. In such cases, the correlation between the markers in
the block dramatically increases the sample variance of the coefficients so that
the markers are not assigned significant p-values even if each would be signifi-
cant if the other were dropped from the model.
We deal with the problem of producing an informative ranked list of selected
markers in our framework by initially fitting an unpenalized regression model
with all markers selected by a given PMR and including relevant covariates,
and calculating p-values for each marker using a standard likelihood ratio test
by comparing the full model to null models where each marker is omitted in
turn. The correlation between all pairs of selected markers is then evaluated,
the pair of markers with the largest correlation is identified, the marker with the
smallest absolute regression coefficient of the two is dropped, and p-values are
then recalculated for the remaining markers. This process is repeated until no
pairwise correlation between remaining markers exceeds 0.1 and each marker
is finally assigned the smallest p-value produced for it during this processes.
This heuristic procedure means that the values cannot be interpreted strictly as
asymptotic p-values [209], but they can be considered as scores indicative of the
significance of the association that ranks the values in terms of confidence while
ensuring at least one marker in the LD block is assigned a p-value rank that can
appropriately reflect a true association.
2.5.6 PUMA software
PUMA implements both linear and logistic models for PMR methods, as well
as single marker analysis, a conditional regression analysis, and the variational
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Bayes multiple regression method VBAY [114]. The software reads genotype
files in TPED format and phenotypes in TFAM as used by Plink [154]. For all
multiple marker methods, we employ a heuristic to remove markers with low
marginal correlations with the phenotype as they are extremely unlikely to be
selected to have nonzero regression coefficients [43, 209]. This is approach is
not novel [43, 209], but accelerates computation and allows flexibility when an-
alyzing extremely large GWAS datasets. The set of markers identified at each
mode of the likelihood surface is stored and is saved in a text file readable by
R. The software is available at http://mezeylab.cb.bscb.cornell.edu/
Software.aspx.
For the single marker analysis, p-values are calculated using a standard F-test
or likelihood ratio test [94] for linear and logistic models, respectively. The con-
ditional regression performs the standard single marker test of association and
includes the significant markers as covariates in a second set of single marker
tests. The minimum of the two p-values from the first and second stage analysis
is then reported for each marker. In this analysis we used a first stage p-value
cutoff of 1× 10−6 and selected the singlemost strongly associatedmarkerwithin
100 Kb to include as covariates in the second stage. We also re-implemented the
approximate Bayesian method VBAY, previously developed by our group [114].
While Bayesian regularized regression methods using a number of prior dis-
tributions as been applied to association mapping using Markov chain Monte
Carlo (MCMC) methods, these cannot simultaneously analyze more than a few
hundred to a few thousand genetic markers at a time [57, 103]. VBAY [114]
uses a variational Bayes approximation to the posterior surface [197] and ap-
plies a hierarchical mixture prior on the regression coefficients so that the large
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majority of coefficients have a high posterior probability of being exactly zero
(see Logsdon et al. [114] for a more detailed discussion of this method). Within
PUMA, we re-implemented VBAY and added the capability to analyze case-
control phenotypes, where we increased the power to detect weak associations
for case-control phenotypes by approximating a logistic regression by modeling
the error distribution with a Student t-distribution with 7.3 degrees of freedom.
This parameterization has the smallest squared error loss of any t-distribution
with respect to the logistic error function [1, 138]. Moreover, we address the
multimodality of the posterior surface by exploring many posterior modes and
applying Bayesian model averaging [71] in order to weight the contribution of
eachmode to the posterior probability of association for eachmarker. The VBAY
algorithm was run with 1000 restarts to explore the non-convex posterior sur-
face. VBAY reports the posterior probability, between 0 and 1, that each marker
is associated with the phenotype.
2.5.7 PUMA software recommended usage
The default settings of PUMA are our recommended settings for a GWAS analy-
sis, which are the same procedures we followed for our analysis of the WTCCC
data here:
1. Marker imputation: Beagle [18] was used to impute missing genotypes,
but other methods can be used. Alternatively, PUMA fills in missing data
with the mean of each marker.
2. Inclusion of fixed covariates: Identify relevant covariates and principal
components and perform single marker analysis so that the correspond-
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ing QQ plot and λGC [34] are acceptable. Results from the single marker
analysis must be acceptable before applying PMR methods.
3. Marker filtering: We applied a pre-screening filter based on p-values from
single marker analysis using a cutoff of 0.01.
4. Number of restarts: The penalized likelihood for the 1D-MCP, 2D-MCP,
NEG and LOG penalties is non-convex so 100 reorderings were used to
explore the multimodal surface for each setting of the tuning parameters.
5. Performance assessment: We recommend assessing the fit of a PMRmodel
by including the selected markers as covariates in a subsequent single
marker analysis. Too much inflation or deflation of the p-values indicates
that the PMR method may be overfitting the data.
6. Threshold determination: We have demonstrated that the reported p-
value score statistics are valuable at prioritizing the top hits as well as
novel weak associations, so assessing the list in rank order is the suggested
strategy for minimizing false positives. For example, in our current analy-
ses we examined at most the top 30 hits for each method combined across
the three diseases, which limited our focus to markers with a p-value score
of < 1× 10−7 for 2D-MCP, < 1× 10−6 for all other PMR methods, and for
comparison, a posterior probability of > 0.97 for VBAY.
2.5.8 GWAS simulation study
Our approach was to simulate different sized GWAS experiments where
we used the real genetic markers for unrelated European individuals from
the Multi-Ethnic Study of Atherosclerosis (MESA) [13] genotyped on the
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Affymetrix 6 platform. Larger sample sizes were generated by drawing hap-
lotypes from existing individuals in order to avoid the confounding effect of
population structure [150]. For each simulated GWAS dataset, we considered
different sample sizes (n = 1000, 2000, 5000) with equal numbers of case and
control phenotypes simulated under an additive threshold model with a dis-
ease prevalence of 50%, using the GCTA program [216], and that different
numbers of susceptibility loci (q = 10, 20, 30, 50) contributed to phenotype her-
itability, where the total contribution of these loci to heritability was varied
(h2 = 30, 40, 50, 60%). Coefficients were drawn from a Γ(1, 1), independent of
allele frequency, so that most effect-sizes were very small as determined by the
marginal heritability calculated by GCTA [216]. We considered 20 replicates
per simulation condition to give 960 simulated GWAS datasets. Causal variants
affecting the phenotype were selected uniformly from the set of genetic mark-
ers with minor allele frequency (MAF) > 5%. We followed typical array-based
GWAS by omitting the causal variants from the analysis so a susceptibility locus
must be identified bymarkers in linkage disequilibriumwith the causal variant.
Following the performance evaluation of previous studies [9, 72], a marker was
considered a true positive hit if it had r2 ≥ 0.05 with a causal marker, other-
wise it was considered a false positive hit. Since a causal variant may be tagged
by multiple true positive markers, the true positive count is defined as the to-
tal number of causal variants tagged when all true positive hits are considered
together. Alternatively, since false positive hits will often fall in clusters in the
same linkage disequilibrium block, we assign each to a 100 kb cluster centered
at the most significant hit in that cluster. The false positive count is then de-
fined as the number of such false positive clusters. We note this is a strategy for
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assessing the performance properties that will be of greatest interest to GWAS
practitioners since it focuses on correct identification of tag markers that are in
high linkage disequilibrium (LD) and in close physical proximity to the location
of the true causal alleles, while considering a strict control of the FDR.
2.5.9 Analysis of WTCCC data
To run the data analysis we used the same quality control filters as in the Well-
come Trust Case Control Consortium, first by excluding 809 individuals because
of poor sample quality, non-Caucasian ancestry, or a high degree of relatedness
[205]. An additional individual was removed for being an outlier by princi-
pal components analysis [150]. Marker locations and genetic map are based
on reference assembly GRCh37/hg19 and dbSNP v131. Next, the same study-
wide missing data rate and deviation from Hardy-Weinberg equilibrium cut-
offs were used for each set of cases as in the original study [205], with an addi-
tional filter to only includemarkers in the analysis with a minor allele frequency
greater than 0.05 in each combined case-control population, leaving approxi-
mately 360,000 markers for each combined case-control data set. We used the
CHIAMO calling scores to set data to missing, where any call with a score of
less than 0.90 was set to missing [205]. To impute this sporadic missing data we
used Beagle [18], with the default settings and allocating a maximum of 3000
MB of memory, where the sporadic missing data for each cohort was imputed
separately. The same set of controls (1958 Birth Cohort (58C) and UK Blood Ser-
vice sample (NBS)) were used for each set of cases as in the original study [205].
Finally, the PMR and single marker analyses included sex as a covariate along
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with the first two principal components of the genotype matrix.
In order to explore the biological function, relevant pathways and possible dis-
ease implications of each gene near a significantly associated marker, we mined
public databases including GenBank [12], Pfam [153], KEGG [82], OMIM [62],
GeneCards [177] as well as the HuGE database [218] of known GWAS hits and
known gene-phenotype links. We also conducted an extensive literature search
with each gene name and relevant phenotypes.
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CHAPTER 3
CORRECTING FOR POPULATION STRUCTURE AND KINSHIP USING
THE LINEARMIXEDMODEL: THEORY AND EXTENSIONS
3.1 Abstract
Population structure and kinship are widespread confounding factors in
genome-wide association studies (GWAS). It has been standard practice to in-
clude principal components of the genotypes in a regression model in order to
account for population structure. More recently, the linear mixed model (LMM)
has emerged as a powerful method for simultaneously accounting for popula-
tion structure and kinship. The statistical theory underlying the differences in
empirical performance between modeling principal components as fixed versus
random effects has not been thoroughly examined. We undertake an analysis
to formalize the relationship between these widely used methods and eluci-
date the statistical properties of each. Moreover, we introduce a new statis-
tic, effective degrees of freedom, that serves as a metric of model complexity
and a novel low rank linear mixed model (LRLMM) to learn the dimension-
ality of the correction for population structure and kinship, and we assess its
performance through simulations. A comparison of the results of LRLMM and
a standard LMM analysis applied to GWAS data from the Multi-Ethnic Study
of Atherosclerosis (MESA) illustrates how our theoretical results translate into
empirical properties of the mixed model. Finally, the analysis demonstrates the
ability of the LRLMM to substantially boost the strength of an association for
HDL cholesterol in Europeans.
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3.2 Introduction
Population structure and kinship are widespread confounding factors in
genome-wide association studies (GWAS) that can decrease power and increase
the false positive rate of tests of association [152]. As a result, it is common
practice to infer population structure and kinship based on genome-wide SNP
data and to exclude problematic individuals or account for these effects in the
test of association [152]. Principal components analysis (PCA) is widely used
to detect population structure [144]. The inferred principal components captur-
ing the genetic ancestry of each individual are often included as fixed effects in
a regression-based test of association in order to account for population struc-
ture [150, 152]. More recently, a linear mixed model (LMM) that considers the
genome-wide similarity between all pairs of individuals was proposed to ac-
count for population structure, known kinship as well as cryptic relatedness
[83, 84], and recent technical advances have made such models tractable for
very large datasets [83, 108, 146, 182, 230].
While simple tests of association assume statistical independence between in-
dividuals, population structure and kinship indicate covariance between indi-
viduals based on the genetic similarity between individuals and the heritability
of the phenotype [83]. Since it is well established that ignoring this covariance in
a test of association produces deflated p-values that do not follow a uniform dis-
tribution under the null [34], it is common to apply a LMM or include principal
components as fixed effects in order to model the dependence structure [152].
Both approaches model this covariance between individuals, and both can be
stated as regressing the phenotype on principal components of the genotype
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matrix [8, 79, 216] so that the LMM essentially includes principal components
as a random effect rather than a fixed effect. While the top principal compo-
nents capture population structure, explicitly modeling the pairwise related-
ness between all individuals captures both population structure and kinship
[83, 87, 152, 207]. Thus much recent attention has focused on the LMM since it
shows better empirical performance in modeling the dependence structure of
GWAS datasets [83, 87, 152, 207].
Motivated by the empirical differences between the LMM and including prin-
cipal components as fixed effects, we describe a unified framework that con-
nects these models. This framework facilitates a statistical examination of the
methods’ differing frequentist vs. Bayesian interpretations, their differing ap-
proaches to inference and how these differences drive their empirical proper-
ties. We next introduce a summary statistic, the effective degrees of freedom,
that measures overall model complexity and the influence of each principal
component on the fit of the LMM. Leveraging the unified framework and the
effective degrees of freedom, we propose a novel method, the low rank linear
mixed model (LRLMM) using the algorithm of Lippert et al. [108], that learns
the dimensionality of the correction for population structure and kinship.
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3.3 Methods
3.3.1 Modeling principal components as fixed versus random
effects
Considering thematrix of genotype dataX (n×p) for n individuals and p genetic
markers, where entry Xk,j ∈ {0, 1, 2} represents the number of copies of the
minor allele that individual k has of marker j, the singular value decomposition
underlying principal components analysis (PCA) has the form
X = USVT (3.1)
so that the first i principal components are the first i columns of U (n × n), S
(n × n) is diagonal so that S = diag(s) where s contains singular values corre-
sponding to each principal component, V (p × n) stores the loadings on each
marker, and each marker inX has been mean centered and scaled [144]. Includ-
ing the first i principal components as fixed effects in a linear model takes the
form
y = µ+ xjβ +U1:iω + ǫ (3.2)
ǫ ∼ N (0, σ2e)
where y (n × 1) is a vector of phenotype values, µ is the scalar mean term, xj
(n × 1) is the jth marker with scalar regression coefficient β, U1:i are the first
i principal components with coefficient vector ω (i × 1), and ǫ (n × 1) is the
normally distributed residual error term with variance σ2e . Principal compo-
nents are treated as fixed effects, such that maximizing the likelihood involves
directly estimating all parameters. From a Bayesian perspective, the model does
57
not have an explicit prior on regression coefficients, ω, and thus implies a uni-
form prior. Furthermore, scaling each principal component by any value yields
a statistically equivalent model with respect to the genetic term, xjβ, since the
prior on the coefficients, ω, is implicitly uniform.
Now consider the linear mixed model (LMM)
y = µ+ xjβ +α+ ǫ (3.3)
α ∼ N (0,Kσ2a)
ǫ ∼ N (0, σ2e)
where α (n× 1) is a random effect vector with a multivariate Gaussian prior,K
(n × n) is the genetic similarity matrix between all pairs of individuals so that
Kk,l represents the similarity between individuals k and l, and σ
2
a is the addi-
tive genetic variance. Here population structure is treated as a random effect
and fitting the model involves integrating over the vector α with respect to the
Gaussian prior so that the likelihood is maximized with respect to σ2a, σ
2
e , µ, and
β [84, 172].
For simplicity, let the genetic similarity matrix K be a simple function of ob-
served genotypes as in Patterson et al. [144], and consider the singular value
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decomposition from equation (3.1) and the factorization ofK
K = XXT (3.4)
= USVT (USVT )T
= USVTVSUT
= USV−1VSUT
= US2UT
= US(US)T
= RRT
so that the columns of U are the principal components of the genotype matrix,
X, exactly as in equation (3.1), and, by construction, the columns of R (n ×
n) are the principal components weighted by their respective singular values.
We note that each principal component Ut has a singular value st and eigen-
value s2t . Using the property of a multivariate Gaussian that φ ∼ N (m,Σ) =⇒
Bφ ∼ N (Bm,BΣBT ), and the decompositions in (3.4), it is apparent that γ ∼
N (0, σ2a) =⇒ Rγ ∼ N (0,Kσ2a), so the LMM (3.3) can be rewritten equivalently
as
y = µ+ xjβ +Rγ + ǫ (3.5)
γ ∼ N (0, σ2a)
ǫ ∼ N (0, σ2e)
Based on the relationship between equations (3.2) and (3.5), it is apparent that
modeling principal components as fixed or random effects share the same un-
derlying regression model. This transformation explicitly formalizes the previ-
ously described relationship between modeling principal components as fixed
versus random effects [8, 79, 216]. While the LMM includes all principal compo-
nents, only i ≪ n principal components are included in the fixed effects model
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since the number of covariates cannot be on the same order as the sample size
while still maintaining reasonable statistical power in a fixed effects model [94].
We discuss the implications of this result in subsequent sections.
We note that while equation (3.4) assumes K is the product of the centered
and scaled genotype matrix [144], this relationship is also consistent with other
genetic similarity metrics that yield a positive semi-definite K. Other closely
related metrics use the estimated rather than observed allele frequencies [150],
adjust the similarity of an individual to itself to reduce sampling variation [215],
use a Gower’s centering to reduce sampling variance [83] or are proportional to
these metrics [8]. Any of these similarity metrics can be used in the LMM or the
principal components of the corresponding similarity matrix can be included as
fixed effects.
3.3.2 Linear mixed model considers principal components’
eigen-values
It is well established that the eigen-value of each principal component serves
as a metric of biological relevance in relation to any underlying population
structure [128, 144]. Thus a method for determining the relevance of a prin-
cipal component to a given phenotype should consider both its eigen-value and
its correlation with the phenotype [99]. Therefore, instead of considering only
the principal components, U, a more sophisticated model should consider the
weighted principal components, R = US, since S = diag(s) weights each prin-
cipal component by its corresponding singular value (i.e. the square root of
60
its eigen-value). However, in the fixed effect model the estimate of the genetic
effect, β, is invariant to the scale of the principal components due to the uni-
form prior implied in equation (3.2). Thus the fixed effect model assumes that
each principal component has equal prior probability of being relevant to the
phenotype. Alternatively, the LMM explicitly models the scale of the weighted
principal components in equation (3.5). The LMM considers both the eigen-
value and correlation with the phenotype when determining the relevance of
each principal component to the phenotype. Moreover, the LMM’s Gaussian
prior on regression coefficients implies the biologically desirable property that
a principal component with a larger eigen-value has a higher prior probability
of being relevant to the phenotype [206].
3.3.3 Inference methods
Since modeling principal components as fixed or random effects share the un-
derlying regression model, the differences in their ability to account for popu-
lation structure and kinship [83, 87, 152, 207] can be attributed to the different
inference methods and the number of principal components included. Yet the
substantial theoretical and practical consequences of these differences have not
been examined. With the goal of elucidating the statistical differences between
modeling principal components as fixed versus random effects, we consider the
theoretical properties of exact inferencemethods for the LMM [84, 108, 146, 230].
We note that our discussion also applies to approximate LMM methods since
they approximate other aspects of the model [83, 182, 225].
In both fixed and random effects models, the parameter of interest for the hy-
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pothesis test is the coefficient β corresponding to the effect of a single genetic
marker, xj , so that the coefficients ω or γ corresponding to the principal com-
ponents are so-called nuisance parameters not of direct interest. The difference
between the methods lies in how the statistical inference treats these nuisance
parameters. The fixed effect model necessarily incorporates only i ≪ n prin-
cipal components and maximizes the likelihood with respect to all coefficients
so that the hypothesis test is conducted at the maximum likelihood estimates of
the nuisance parameters. Thus the fixed effects model implies the likelihood
Lfixed(β, µ,ω, σ
2
e |y) = N (y|µ+ xjβ +U1:iω, σ2e) (3.6)
which has i + 3 free parameters to be estimated from the data. Therefore i de-
grees of freedom are used to correct for population structure.
Alternatively, the LMM includes all principal components in the model and in-
tegrates over the random effect with respect to its prior distribution. The likeli-
hood can be stated in terms of the genetic similarity matrix,
LLMM(β, µ, σ
2
a, σ
2
e |y) =
∫
N (y|µ+ xjβ +α, σ2e) N (α|0,Kσ2a) dα (3.7)
[172] or equivalently in terms of the scaled principal components,
LLMM(β, µ, σ
2
a, σ
2
e |y) =
∫
N (y|µ+ xjβ +Rγ, σ2e) N (γ|0, σ2a) dγ
based on the equivalence between equations (3.3) and (3.5). While other equiv-
alent forms of the likelihood are used for estimation in practice [84, 108], stating
the likelihood in this way formalizes the Bayesian interpretation of the LMM
where a Gaussian prior is placed on the regression coefficients of the principal
components and the effect of population structure and kinship is integrated out.
Due to the integration over nuisance parameters, the LMM is able to include all
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principal components in the statistical model, yet estimate only 4 free parame-
ters from the data.
3.3.4 Dimensionality of population structure versus kinship
Population structure and kinship are both confounding factors in GWAS since
they produce covariance between individuals’ phenotype values. Yet the di-
mensionality of these two processes are different. Population structure is a low
dimensional process embedded in a high dimensional space so that a relatively
small number of principal components represent the underlying population ge-
netics [128, 144]. Therefore, a small number of principal components are ad-
equate to account for population structure in GWAS datasets [150, 152]. Con-
versely, kinship is a high dimensional process since small sets of individuals are
very closely related while being unrelated to the remaining individuals. Con-
sider an idealized example of independent parent-offspring duos so that the
coefficient of coancestry between parent and offspring is 0.5, and 0 between all
other individuals. It follows directly that the corresponding coancestry matrix
is block diagonal and the eigen-spectrum has a long tail so that all eigen-values
are nonzero (Figure 3.1). In practice, the coefficient of coancestry is usually re-
placed by the observed genetic similarity so that the signature of kinship will
not be as clean, and some trailing eigen-values will be due to stochastic noise.
Nonetheless, kinship is a high-dimensional process that cannot be captured by
a small number of principal components. Therefore, kinship must be modeled
using a random effect as has long been done in the field of quantitative genetics
[66, 117].
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Figure 3.1: Genetic similarity matricies and their eigen-spectra. A) Block
diagonal matrix of coefficients of coancestry for 50 parent-
offspring duos. B) Eigen-spectrum of kinship matrix from (A).
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3.3.5 Effective degrees of freedom of the linear mixed model
The degrees of freedom of a regression model is a widely used statistic that re-
flects the number of parameters estimated from the data. In a standard fixed
effects model, the total degrees of freedom is a predetermined value and each
regression coefficient uses 1 degree of freedom so that the total degrees of free-
dom equals the number of coefficients estimated. Moreover, the degrees of free-
dom of a fixed effects model must be substantially less than the sample size in
order to maintain reasonable statistical power [94]. In standard GWAS anal-
ysis population structure is modeled as a low dimensional process [128, 144]
so that the degrees of freedom devoted to the principal components is a small
fraction of the sample size [150, 152]. Since the LMM is able to model both pop-
ulation structure and kinship by considering the full eigen-spectrum, it would
therefore be useful to consider the degrees of freedom of the LMM. Due to the
parameter-reduction property of the LMM resulting from the integration over
nuisance parameters, we consider an analogous statistic, the “effective degrees
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of freedom”, dfe. We consider dfe in the context of the statistical properties of
the LMM as well as its biological interpretation.
The formula for effective degrees of freedom is based on the fitted response val-
ues in the regression model. Ignoring fixed effects, since they each use 1 degree
of freedom, the estimated trait values based on only the random effect are
yˆ = K(K+ Iδ)−1y (3.8)
= Hy
where δ = σ
2
e
σ2a
and H is defined by construction [172]. This is recognizable as
a “linear smoother”, whereby the fitted response values are a linear function
of the observed responses [64]. In such a case the effective degrees of freedom
used by a linear smoother is defined as
dfe = tr(H) (3.9)
where tr(.) gives the sum of the diagonal entries [64]. We note by way of
comparison that a fixed effects model is also a linear smoother where yˆ =
X(XTX)−1XTy = Hy and that tr(H) is equal to number of regression coeffi-
cients, thus satisfying our intuition about degrees of freedom. This metric of
model complexity has seen wide adoption in the interpretation of penalized
splines and nonparametric regression [64, 162]. The effective degrees of free-
dom for the LMM is more interpretable in the equivalent form
dfe =
∑
i
s2i
s2i + δ
(3.10)
where s2i is the i
th eigen-value ofK forming the diagonal of S2 in equation (3.4)
(see Appendix for derivation).
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This form of the effective degrees of freedom facilitates an interpretation of the
influence of each principal component that is composed of a marker-based el-
ement, s2i , and a phenotype based element, δ. It is apparent that the Gaussian
prior in the LMM causes the influence of the ith principal component to be a
nonlinear function of the magnitude of its corresponding eigen-value, s2i . This
formulation satisfies our intuition for dfe since the contribution of a single prin-
cipal component is between 0 and 1 so that dfe, which is the sum of the con-
tributions of all principal components, is naturally bounded between 0 and the
number of principal components. Moreover, while s2i has a local effect on the
influence of each principal component separately and is independent of the phe-
notype, estimating δ adaptively learns the effective degrees of freedom based on
the correlation of the principal components with the phenotype and has a global
effect by influencing the contribution of all principal components. In addition,
it follows that the effective degrees of each principal component decreases with
its eigen-value.
Returning to the biological interpretation of the effective degrees of freedom,
we note that LMM relates the genetic similarity between individuals to the
heritability of the trait [215], as well as population structure and kinship
[19, 83, 84, 150, 152]. Thus the LMM uses the estimated “pseudo-heritability”
of the trait in the present set of individuals to determine how strongly to correct
for population structure and kinship. This data-adaptive property reflects the
ability of the LMM to learn dfe directly from the data. Moreover, the dfe statistic
is composed of heritability, population structure and kinship so that the value
of dfe reflects the “effective dimensionality” of the correction for confounding.
Thus for a given heritability, a small dfe value indicates that only population
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structure is relevant, while a large value indicates the high-dimensional kinship
process is also relevant.
3.3.6 Low rank linear mixed model
To this point we have considered the standard LMM where the genetic similar-
ity matrix is full rank and all principal components make a contribution to the
phenotype. Yet the correction for confounding due to population structure and
kinship should not necessarily be full rank. Including principal components
that are not biologically relevant to the given phenotype can dilute the influence
of relevant principal components and degrade the quality of the correction since
the random effect is governed by a single global parameter, δ. Moreover, the bi-
ological relevance of a principal component to the phenotype depends both on
its eigen-value and its correlation with the phenotype [99, 144]. Building on the
algorithm of by Lippert et al. [108] for increasing computational efficiency for
large datasets, we propose a novel method that uses the LRLMM framework
and the effective degrees of freedom to identify principal components relevant
to the current phenotype. In doing so we learn the rank of the correction for
population structure and kinship.
In order to identify relevant principal components, we fit a LRLMM where
the rank varies from 0, where we fit the standard linear model, to the sample
size, where the full rank LMM is used. Principal components are added to the
model sequentially and the log-likelihood and effective degrees of freedom are
evaluated for each rank. The best model is then selected using the Bayesian
Information Criterion (BIC) [168]. Since the order in which principal compo-
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nents are added to the model affects the optimal rank, we consider different
orderings of the principal components based on 1) eigen-value, 2) squared cor-
relation between principal component and phenotype (corSq), 3) eigen-value
multiplied by squared correlation between principal component and phenotype
(corSq*eigen-value) [99], 4) degrees of freedom from fitting each principal com-
ponent individually (DF).
3.4 Results
3.4.1 Simulations
Our low rank linear mixed model (LRLMM) is designed to empirically learn the
optimal rank of the confounding effect of population structure and kinship. We
assessed performance of the LRLMM by simulating continuous phenotypes us-
ing the normal model from equation (3.5) where a low rank model corresponds
to setting most coefficients in γ to zero. We set h2 = σ
2
a
σ2a+σ
2
e
= 0.40, µ = β = 0,
drew nonzero coefficients fromN (0, 100), and considered 2000 individuals with
10,000 replicate simulations. The genetic marker, x, was generated based on an
allele frequency drawn uniformly between 5% and 50%. Low dimensional pop-
ulation structure was modeled by randomly selecting 30 principal components
from the first 90 to contribute to the phenotype. The high-dimensional pro-
cess of kinship combined with population structure was modeled by having all
principal components contribute to the phenotype. In both cases principal com-
ponents are scaled by the square root of their eigen-value as in equation (3.5).
The methods were assessed based on the accuracy of the estimates of genetic
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Figure 3.2: Simulation results showing mean squared error of the genetic
effect, βˆ, for linear mixed model (LMM) and low rank linear
mixed model (LRLMM) for confounding due to A) popula-
tion structure and B) population structure and kinship. Results
are shown for the LRLMM using only the truly active princi-
pal components (True), full rank LMM (Full), and the LRLMM
with four orderings of the principal components: eigen-value,
squared correlation with phenotype (corSq), both eigen-value
and squared correlation with phenotype (corSq*eigen-value)
and degrees of freedom from fitting each principal component
individually (DF). Bars indicate the estimated mean squared
error of the genetic effect, βˆ, along with the 1%, 10%, 90% and
99% confidence interval.
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effect expressed as the mean squared error (MSE) of βˆ (Figure 3.2).
In the case of population structure the full-rank LMM had the largest MSE (Fig-
ure 3.2A). The LRLMM sorting principal components by correlation with the
phenotype, correlation and eigen-value, or degrees of freedom had MSE close
to that of the true model where only relevant principal components are used.
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Sorting principal components by eigen-value also produced a large MSE since
the eigen-value alone was not a good metric of the relevance of a principal com-
ponent. In the presence of both population structure and kinship, the full-rank
model is the true model so it yields the smallest MSE (Figure 3.2B). The LRLMM
methods all give larger MSE values since they do not model the full eigen-
spectrum of the genetic similarity matrix. In general, three LRLMM methods
perform best when the confounding effect is low-dimensional, while the full-
rank LMM performs best when when the confounding effect is also full-rank.
3.4.2 Data analysis
Our analysis of GWAS data from four populations and two phenotypes from
the Multi-Ethnic Study of Atherosclerosis (MESA) [13] (Table 3.1) illustrates
properties of the LMM and demonstrates the ability of the LRLMM to boost the
strength of an association signal. Eigen-spectra of the genetic similarity matri-
ces from four MESA populations as well as the matrix of coancestry coefficients
based on the known pedigree from the Framingham Heart Study [32] illustrate
the different dimensionality of population structure and kinship (Figure 3.3).
It is apparent that population structure is low dimensional so the eigen-values
decay very quickly in the MESA populations, while kinship from the Framing-
ham pedigree shows a very long tail indicative of a high-dimensional process.
In addition, the LMM relates the eigen-spectrum of the genetic similarity matrix
to the phenotype and its heritability, and this relationship is reflected by the ef-
fective degrees of freedom for each principal component (Figure 3.4). Thus the
effective degrees of freedom, normalized by the sample size, used by the LMM
for height is substantially larger than for HDL cholesterol (Figure 3.6A), since
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height is known to have a larger heritability [95, 204]. Moreover, the fact that the
effective degrees of freedom is a substantial fraction of the sample size indicates
that the LMM models the high-dimensional confounding effect of kinship. We
note that the heterogeneity among populations can be attributed either to differ-
ential population structure or kinship, or to stochastic effects. Finally, we note
that the LMM was fit by maximum likelihood here, but estimation by REML
has little effect (Figure 3.5).
Table 3.1: Sample size for each population and phenotype from the Multi-
Ethnic Study of Atherosclerosis (MESA) dataset.
Asian Hispanic European African American combined
HDL cholesterol 772 1436 2481 1584 6273
height 775 2104 2522 2528 7929
Applying the LRLMM sorting by degrees of freedom from fitting each principal
component individually (LRLMM-DF) selects effective degrees of freedom that
are substantially smaller than for the full-rank model and the effective degrees
of freedom is generally larger for height than for HDL cholesterol (Figure 3.6B).
Morever, the width of the 95% confidence interval is also substantially smaller.
Applying the LRLMM-DF for association testing for HDL cholesterol in Euro-
peans substantially boosts the signal from markers on chr8 between positions
19,852,309 and 19,869,675 compared to a standard linear model (Plink [154]) and
three versions of the LMM (EMMAX [83], GEMMA [230], fastlmm [108]) (Fig-
ure 3.7, Figure A.23). The boost in the association signal is more interpretable
in a zoom-in manhattan plot illustrating that the LRLMM-DF method produces
many more p-values that exceed the Bonferroni cutoff (Figure 3.8). This region
has previously been associated with HDL cholesterol [93, 203], so LRLMM-DF
is able to strengthen the signal of a replicated association.
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Figure 3.3: Comparison of eigen-spectra due to population structure and
kinship. The eigen-spectrum based on the known pedigree
from 3063 individuals from the Framingham Heart Study re-
flects kinship, while the eigen-spectrum for four populations
from theMulti-Ethnic Study of Atherosclerosis (MESA) reflects
both population structure and kinship. Eigen-values for each
dataset are normalized by the maximum eigen-value so that
each spectrum has a maximum of 1.
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Figure 3.4: Effective degrees of freedom for each principal component
based on a linear mixed model (LMM) analysis of HDL choles-
terol for four populations from the Multi-Ethnic Study of
Atherosclerosis (MESA) dataset. Total effective degrees of free-
dom for each population are shown in the legend.
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Figure 3.5: Fraction of available degrees of freedom used by the lin-
ear mixed model (LMM) to account for population structure
and kinship estimated using restricted maximum likelihood
(REML). Effective degrees of freedom normalized by sample
size are show for six phenotypes and four populations from the
Multi-Ethnic Study of Atherosclerosis (MESA) plus the com-
bined dataset. Error bars indicate 95% confidence intervals
based on the log-likelihood surface.
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Figure 3.6: Fraction of available degrees of freedom used to account for
population structure and kinship by A) the linear mixed model
(LMM) and B) the low rank linear mixed model (LRLMM)
sorting by degrees of freedom of each principal component fit
individually (LRLMM-DF). Effective degrees of freedom nor-
malized by sample size are shown for two phenotypes and
four populations from the Multi-Ethnic Study of Atheroscle-
rosis (MESA) plus the combined dataset. Error bars indicate
95% confidence intervals based on the log-likelihood surface.
Note the large difference in the scales between (A) and (B).
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Figure 3.7: Quantile-quantile plot for association tests for HDL cholesterol
in Europeans. Results are shown from a standard linear model
(Plink [154]), 3 versions of the linear mixed model (EMMAX
[83], GEMMA [230], fastlmm [108]), and the low rank linear
mixedmodel with 4 orderings of the principal components. We
note that LRLMM using eigen-value and corSq*eigen-value or-
derings selected no principal components correction and thus
give the same p-values as Plink. λGC indicates the genomic
control value [34].
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Figure 3.8: Manhattan plot of chromosome 8 showing 19.6 Mbp to 20.1
Mbp where the low-rank linear mixed model (LRLMM) or-
dering principal components by degrees of freedom based on
the fit of LRLMM with each principal component individually
(LRLMM-DF). P-values from fastlmm [108] are shown for com-
parison. Dashed line indicates Bonferroni correction of 5% for
650,000 markers. Linkage disequilibrium is shown in terms of
D’. We note that other methods are omitted for the sake of clar-
ity.
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3.5 Discussion
The linear mixed model (LMM) has become a standard method to account for
the confounding effects of population structure and kinship in GWAS datasets.
[83, 152]. Our theoretical and empirical analysis illustrates the properties of the
LMM and formalizes a biological interpretation of the model. We introduced
the effective degrees of freedom in order to interpret the strength of the correc-
tion for population structure and kinship. A fixed effects model can include
relatively few principal components, yet the LMM models the entire eigen-
spectrum of the genetic similarity matrix. Thus while it is generally suggested
that the degrees of freedom in a regression model be on the order of the square-
root of the sample size in order to maintain reasonable statistical power [94], the
effective degrees of freedom of the full-rank LMM routinely exceeded 40% of
the sample size in our analysis and reached up to 80%. The effect of using such
high effective degrees of freedom on the statistical test of association remains
an open question. Moreover, wide confidence intervals for the effective degrees
of freedom indicate that there is a high degree of uncertainly about the strength
of the correction for population structure and kinship. Alternatively, the confi-
dence intervals for the LRLMM are substantially smaller and are thus less in-
fluenced by stochastic effects. These results indicate that a high-dimensional
correction for confounding may benefit from a fully Bayesian treatment of the
linear mixed model as it would integrate over the uncertainty of the strength of
the correction. Yet the LRLMM would likely not benefit as much since it pro-
duces a low-dimensional fit to the data.
The ability of our low rank linear mixed model (LRLMM) to boost the signal of
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a known association for HDL cholesterol in Europeans indicates that the LMM
can overfit the data so that the random effect absorbs too much of the pheno-
type variance. If the true model is low rank, then the LRLMMwill have greater
power than the LMM. Alternatively, if the true model is high-dimensional then
the full-rank LMM is more appropriate. Since there is no principled way to de-
termine the true dimensionality, our novel LRLMM provides an alternative test
of association that can boost the strength of an association or identify additional
associations if it is a better fit to the data. As there is currently no objective way
to determine which method is more appropriate for a given dataset, we recom-
mend running both the full and low rank methods and examining the resulting
quantile-quantile plots and top associations.
With the growing interest in testing associations of rare variants, new problems
of population structure are arising due to the more recent origin andmore local-
ized distribution of rare compared to common variants [85, 136, 184]. Moreover,
a recent simulation study demonstrated that including principal components
as covariates or using the LMM were not effective at controlling for popula-
tion stratification due to rare variants [123]. While addressing this challenge
will require extensive methodology development and empirical investigations,
the framework discussed here suggests important issues to consider in order to
apply appropriate corrections for population structure and kinship in the next-
generation of GWAS.
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CHAPTER 4
MODELING THE POLYGENIC ARCHITECTURE OF COMPLEX TRAITS
IN THE PRESENCE OF KINSHIP AND POPULATION STRUCTURE: A
UNIFIED STATISTICAL FRAMEWORK
Sophisticated statistical methods that model the biological complexities of
genome-wide association studies (GWAS) can increase the power to detect weak
associations while controlling the false discovery rate. Among the most suc-
cessful methodological developments has been the use of linear mixed models
to correct for kinship and population structure [83, 84, 92, 108, 109, 146, 156,
170, 182, 230]. Independently, multiple-locus methods that explicitly model the
polygenic architecture of complex traits have the potential to increase power to
detect weak associations [9, 39, 57, 65, 72, 103, 114, 192, 209, 214, 227], and we
have previously demonstrated the power of this approach (Chapter 2). Here
we combine these complementary statistical methods into a unified statistical
framework. This penalized linear mixed model is scalable to large datasets and
has direct applications to response prediction and feature selection in the pres-
ence of genetic confounding.
The linear mixedmodel has previously been combinedwith feature select meth-
ods using a LASSO penalty [156] or stepwise regression [170]. Here we propose
statistical, algorithmic and computational developments in order to optimize
the statistical performance and facilitate scaling to large datasets. We develop
novel approaches to tuning nonconvex penalties and determining the optimal
stopping point in regularization path. Leveraging recent work on assessing sig-
nificance of selected features, we produce a well-principled and scalable statis-
tical method applicable to feature selection, hypothesis testing and prediction
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in many contexts. We are currently developing a user-friendly R package based
on these developments.
4.1 Methods
4.1.1 Linear mixed model
Consider the linear mixed model widely used in GWAS analysis [83, 84, 92, 108,
109, 146, 170, 230] and derive parameter updates to reach a local model of the
likelihood. The log-likelihood can be expressed as
ℓ(β, σ2e , σ
2
a) = logN
[
y|Xβ,Kσ2a + Iσ2e
]
(4.1)
= logN [y|Xβ, σ2a(K+ Iδ)] where δ = σ2eσ2a (4.2)
= −n
2
log(2π)− 1
2
log |σ2a(K+ Iδ)| −
1
2
(y −Xβ)T (σ2a(K+ Iδ))−1(y −Xβ) (4.3)
= −n
2
log(2πσ2a)−
1
2
log |K+ Iδ| − 1
2σ2a
(y −Xβ)T (K+ Iδ)−1(y −Xβ) (4.4)
Letting the eigen-decomposition ofK = USUT ,
K+ Iδ = USUT +UUT δ (4.5)
= U(S+ Iδ)UT (4.6)
Plugging (4.6) into the log-likelihood (4.4), the log-likelihood becomes
= −n
2
log(2πσ2a)−
1
2
log |U(S+ Iδ)UT | − 1
2σ2a
(y −Xβ)T (U(S+ Iδ)UT )−1(y −Xβ) (4.7)
= −n
2
log(2πσ2a)−
1
2
log |S+ Iδ| − 1
2σ2a
(y −Xβ)TU(S+ Iδ)−1UT (y −Xβ) (4.8)
= −n
2
log(2πσ2a)−
1
2
log |S+ Iδ|
− 1
2σ2a
([UTy]− [UTX]β)T (S+ Iδ)−1([UTy]− [UTX]β) (4.9)
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Letting y˜ = UTy and X˜ = UTX in order to simplify notation,
= −1
2
[
n log(2πσ2a) + log |S+ Iδ|+
1
σ2a
(y˜ − X˜β)T (S+ Iδ)−1(y˜ − X˜β)
]
(4.10)
Since the covariance matrix is now diagonal, the log-likelihood
ℓ(β, σ2e , σ
2
a) = −
1
2
[
n log(2πσ2a) +
n∑
i=1
log(Si,i + δ) +
1
σ2a
n∑
i=1
(y˜i − X˜iβ)2
Si,i + δ
]
(4.11)
can be evaluate in time linear with the sample size.
Estimation
Taking derivatives of (4.11) gives closed form updates of σ2a and β:
∂ℓ
∂σ2a
= −1
2
(
n
σ2a
− 1
σ4a
n∑
i=1
(y˜i − X˜iβ)2
Si,i + δ
)
= 0 (4.12)
σˆ2a =
1
n
n∑
i=1
(y˜i − X˜iβ)2
Si,i + δ
(4.13)
∂ℓ
∂β
=
1
σ2a
(y˜ − X˜β)T (S+ Iδ)−1X˜ = 0 (4.14)
= y˜T (S+ Iδ)−1X˜− βT X˜T (S+ Iδ)−1X˜ (4.15)
βˆ =
[
X˜T (S+ Iδ)−1X˜
]−1
X˜T (S+ Iδ)−1y˜ (4.16)
=
[
n∑
i=1
1
Si,i + δ
X˜Ti X˜i
]−1 [ n∑
i=1
1
Si,i + δ
X˜Ti y˜i
]
(4.17)
Since updates of σ2a and β have closed forms, the update of the δ becomes a one
dimensional optimization problem by plugging in values of the other parame-
ters. The log-likelihood can thus be expressed as
ℓ(δ) = −1
2
[
n log(2πσˆ2a) +
n∑
i=1
log(Si,i + δ) + n
]
(4.18)
which is a simple function of δ. Since the log-likelihood surface is not con-
vex with respect to δ we apply a one dimensional grid search with a quasi-
Newton optimization method to identify modes of the surface between each
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pair of points on the grid.
The derivation of this part of the model follows Lippert et al. [108] and we omit
the derivation of the low rank mixed model for brevity.
4.1.2 Penalized linear mixed model
Combining the linear mixedmodel with a penalty on the regression coefficients,
β, involves including a penalty term in the log-likelihood so that the penalized
likelihood has the form
ℓ(β, σ2a, δ) = logN
[
y|Xβ, σ2a(K+ Iδ)
]− pλ(β) (4.19)
= −1
2
[
n log(2πσ2a) +
n∑
i=1
log(Si,i + δ) +
1
σ2a
(y˜ − X˜β)T (S+ Iδ)−1(y˜ − X˜β)
]
−
∑
j
p(βj) (4.20)
for an arbitrary penalty p(.).
Estimation
Maximizing the log-likelihood involves iteratively updating each parameter.
Since the updates of σ2a and δ only depend on β through the current residuals
r˜ = y˜ − X˜βˆ, the updates of these parameters remains the same as for the unpe-
nalized model. The regression coefficients, β, are updated using a coordinate-
wise update approached that is scalable to high-dimensional penalized regres-
sion [47, 48].
Considering only terms in the log-likelihood that are relevant to the updates
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of β, the log-likelihood is recognizable as a reweighted penalized regression
system [48]. Letting the weights beW = (S + Iδ)−1, separating out the jth re-
gression coefficient, and using the fact that
y˜ −
∑
k 6=j
x˜kβk − x˜jβj = r˜+ x˜jβj (4.21)
the log-likelihood can be expressed as
ℓ(β, σ2a, δ) ∝ −
1
2σ2a
(y˜ − X˜β)T (S+ Iδ)−1(y˜ − X˜β)−
∑
j
p(βj) (4.22)
= − 1
2σ2a
(y˜ −
∑
k 6=j
x˜kβk − x˜jβj)TW(y˜ −
∑
k 6=j
x˜kβk − x˜jβj)−
∑
j
p(βj) (4.23)
= − 1
2σ2a
(r˜+ x˜jβj)
TW(r˜+ x˜jβj)−
∑
j
p(βj) (4.24)
It follows that the first and second derivatives are
∂ℓ
∂βj
=
1
σ2a
[
(r˜+ x˜jβj)
TWx˜j − x˜TjWx˜jβj
]−∑
j
p′(βj) (4.25)
=
1
σ2a
[
r˜TWx˜j + x˜
T
jWx˜jβj − x˜TjWx˜jβj
]−∑
j
p′(βj) (4.26)
=
1
σ2a
r˜TWx˜j −
∑
j
p′(βj) (4.27)
∂ℓ
∂β2j
= − 1
σ2a
x˜TjWx˜j −
∑
j
p′′(βj) (4.28)
so that the standard Newton-Raphson update with the LASSO model is
β
(s+1)
j = β
(s)
j −
ℓ′(β
(s)
j )
ℓ′′(β
(s)
j )
. (4.29)
Note that this derivation and those below omit the complexities raised by the
fact that p(β) is non-differentiable at the origin. We follow Wu and Lange [210]
on this issue, but omit the details for brevity.
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Estimation: LASSO
For the LASSO penalty [187] the form of the update is
β
(s+1)
j = β
(s)
j +
1
σ2a
r˜TWx˜j − λsign(βj)
1
σ2a
x˜TjWx˜j
(4.30)
=
1
σ2a
β
(s)
j x˜
T
jWx˜j +
1
σ2a
r˜TWx˜j − λsign(βj)
1
σ2a
x˜TjWx˜j
(4.31)
=
β
(s)
j x˜
T
jWx˜j + r˜
TWx˜j − σ2aλsign(βj)
x˜TjWx˜j
(4.32)
Letting z = β
(s)
j x˜
T
jWx˜j + r˜
TWx˜j , the LASSO update is
β
(s+1)
j =
S(z, σ2aλ)
x˜TjWx˜j
(4.33)
where
S(d, λ) =


d− λ d > 0 and λ < |d|
d+ λ d < 0 and λ < |d|
0 λ ≥ |d|
(4.34)
is the soft-thresholding function [47, 48].
Estimation: MCP
If an MCP penalty [221] is used, then the log-likelihood becomes
ℓ(β, σ2e , σ
2
a) = logN
[
y|Xβ,Kσ2a + Iσ2e
]−∑
j
pλ,a(βj) (4.35)
where
pλ,a(β) =


λβ − β2
2a
β ≤ aλ
1
2
aλ2 β > aλ
(4.36)
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It follows the directly from above derivations and the derivation of penalized
likelihood models for MCP in Chapter 2 that coordinate-wise update for β ≤ aλ
is
β
(s+1)
j = β
(s)
j +
1
σ2a
rTWxj − λ+ β
(s)
j
a
1
σ2a
xTjWxj − 1a
(4.37)
=
β
(s)
j (
1
σ2a
xTjWxj − 1a) + 1σ2a r
TWxj − λ+ β
(s)
j
a
1
σ2a
xTjWxj − 1a
(4.38)
=
1
σ2a
β
(s)
j x
T
jWxj +
1
σ2a
rTWxj − λ
1
σ2a
xTjWxj − 1a
(4.39)
=
β
(s)
j x
T
jWxj + r
TWxj − σ2aλ
xTjWxj − σ
2
a
a
(4.40)
=
S(z, σ2aλ)
xTjWxj − σ
2
a
a
(4.41)
4.1.3 A hypothesis test of selected features
Hypothesis testing is often the ultimate goal of regression modeling. Yet fea-
ture selection methods do not typically return a p-value or other confidence
metric that reflects the significance of each selected feature. Recent work has
produced a number of subsampling methods that perform feature selection on
a subset of the data and either perform hypothesis testing on a complementary
subset [202], perform this process on many subsets to produce a distribution of
p-values [131], or return the fraction of times that each feature is selected [130].
Yet these methods are computationally expensive and are problematic when
considering highly correlated features, such as in GWAS datasets [2].
In recent work, Lockhart et al. [112] has developed a very simple hypothesis test
for the addition of each feature as the penalty is gradually relaxed. The simplic-
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ity of the test statistic makes it directly applicable to penalized feature selection
models using LASSO, MCP or another penalty. Moreover, the test should be
approximately correct for the penalized linear mixed models described here.
4.1.4 Determining optimal tuning parameter from regulariza-
tion path
Selecting the optimal value of the tuning parameter governing the slope at the
origin as been widely studied [26, 48, 198, 199, 211, 224], yet still remains an
issue in data analysis. Based on the work of Lockhart et al. [112], a hypothesis
test produces an interpretable confidence metric for each value of the tuning
parameter and can serve as the criterion for determining the stopping point in
the regularization path. We note that this approach naturally incorporates both
the sample size and the number of features into the stopping criteria.
4.1.5 Selecting second tuning parameter for MCP
MCP has two tuning parameters, λ, which determines the derivative infinites-
imally close to the origin, and a so that the penalty becomes constant at aλ
(Equation 4.36, Figure 4.1). While tuning the slope near the origin has been well
studied, selecting a remains an open question. Here we propose a novel strat-
egy based on fixing the value of aλ. We note that the MCP no longer shrinks
coefficient estimates that surpass this value, since the derivative is zero. Essen-
tially, this is akin to saying that we have high confidence that all coefficients
greater than aλ are truly nonzero. This interpretation motivates the question:
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Figure 4.1: The MCP penalty
regression coefficient
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For a given dataset, how large must a coefficient estimate be before we have
high confidence that it is truly nonzero? We can thus set aλ to the value that
answers this query and set a based on the value of λ. Formalizing this intuitive
motivation based on statistical theory, we can determine the value aλ by refer-
ring to standard power calculations for the linear model with Gaussian error.
Based on the dataset given and the desired confidence level this theory yields a
simple form the value of aλ.
Consider a Gaussian linear model of the form
y = µ+
m∑
j=1
xjβj + ε (4.42)
ε ∼ N (0, σ2) (4.43)
with n samples. Using standard results from statistical theory [23], we can as-
sess the power of an F-test of the jth coefficient, βj , to reject the null hypothesis
of βj = 0 based on n, σ
2, var(xj), α (the type I error rate), and the value of βj
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under the alternative. In general, the power can be expressed as
power = p(F (1, n−m− 1, γ) ≥ t) (4.44)
where F (1, n − m − 1, γ) is the cumulative distribution function of the F-
distribution, t = F1−α,1,n−m−1 is the critical value based on the 1 − α quantile
of the F-distribution, γ is the test statistic defined as
γ =
nβ2j (1−R2xj |x−j)var(xj)
σ2
(4.45)
and R2
xj |x−j
denotes a conditional correlation between xj and all other variables.
For simplicity, we can deal with a univariate regression (with a mean term) so
that the test statistic becomes
γ =
nβ2j var(xj)
σ2
(4.46)
and power becomes
power = p(F (1, n− 2, γ) ≥ F1−α,1,n−2). (4.47)
Based on this theory, the value of aλ can be expressed as a function of properties
of the data n and var(xj); an estimate of the residual variance, σ
2, which can be
informed by the estimated heritability of the trait; the desired confidence level,
expressed as the desired type I error, which can be informed by the multiple
testing burden; and the desired power. We note that this approach depends on
the MCP penalty reaching a constant value for a finite coefficient value. Since
the LOG and NEG penalties [72, 124] (Chapter 2) reach a constant value only
in the limit, further extensions would have the be made to accommodate these
penalties.
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To our knowledge, only Mazumder et al. [124] have developed a principled
method to address the issue of tuning parameters for nonconvex penalty. In
their work, Mazumder et al. [124] defines the effective degrees of freedom based
on λ, a and the fit to the data, and reparameterize the penalty to have constant
effective degrees of freedom across values of a. So while they do not actually set
a or aλ explicitly, the reparameterization and constraint has the same general
motivation, but without the reference to power calculations.
Given the relevant values, the coefficient value at which the derivative becomes
zero is
aλ = argmin
β
∣∣∣∣power− p
(
F
(
1, n− 2, nβ
2var(xj)
σ2
)
≥ F1−α,1,n−2
)∣∣∣∣ (4.48)
by combining (4.46) and (4.47). Since λ is known at each step in the regulariza-
tion path and aλ is constant based on (4.48), a is easily calculated.
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APPENDIX A
APPENDIX
A.1 Efficient coordinate-wise gradient descent algorithms for
high-dimensional penalized generalized linear models
Here we derive the algorithms used by PUMA for efficient estimation in penal-
ized generalized linear models (GLM). In order to make the derivations general
so that they are applicable to GLM’s with normal or binary responses, we use
the following standard notation to describe GLM’s as in McCullagh and Nelder
[125].
X matrix of features
β vector of regression coefficients
y vector of observed responses
η(s) value of linear predictor at sth iteration
ℓ(η) log-likelihood function of the data based on η
ℓ(β) reparameterized log-likelihood based on β
µ estimated response on the same scale at the observed response, y
V (µ) function of estimated response that is proportional to var(y)
g(.) link funtion for a GLM so that g−1(η) = µ
θ cannonical parameter of the GLM
b(θ) defined so that likelihood is a member of the exponential family
v
∂ℓ(η)
∂η
W - ∂
2ℓ(η)
∂η∂ηT
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A.1.1 Log-likelihood of a generalized linear model
Consider the log-likelihood of a GLM as a function of η and obtain the first
derivative using
µi = b
′(θi) = g
−1(ηi) (A.1)
and
g(µi) = ηi = Xiβ (A.2)
where vectors are indexed by i [125]. Since the response comes from a distribu-
tion in the exponential family, the log-likelihood in cannonical form satisfies
ℓ(η) ∝
n∑
i=1
[yiθi − b(θi)] (A.3)
The derivative of ℓ(η) follows from the standard properties of a GLM as in Mc-
Cullagh and Nelder [125]:
∂ℓ
∂ηi
= [yi − b′(θi)]∂θi
∂ηi
(A.4)
= [yi − b′(θi)] ∂θi
∂µi
∂µi
∂ηi
(A.5)
= [yi − b′(θi)] 1
b′′(θi)
1
g′(µi)
(A.6)
= [yi − b′(θi)] 1
V (µi)g′(µi)
(A.7)
=
(yi − µi)
V (µi)g′(µi)
(A.8)
Using the fact that V (µi)g
′(µi) = 1 if the cannonical link is used and expressing
the derivative in matrix notation:
vn×1 =
∂ℓ
∂η
(A.9)
= y − µ (A.10)
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The second derivative is:
∂2ℓ
∂ηi∂ηi′
=
∂µi
∂ηi′
(A.11)
=
1
g′(µi′)
(A.12)
Let W denote the negative Hessian and notice that the off-diagonal elements
are zero:
Wn×n = − ∂ℓ
∂η∂ηT
(A.13)
= diag
[
1
g′(µ)
]
(A.14)
If the cannonical link is used, the formula forW is:
response g(µi) g
′(µi) W
normal 1 1 diag(1)
binomial log µi
1−µi
1
µi(1−µi)
diag [µ(1− µ)]
A.1.2 Quadratic approximation to the log-likelihood
The standard iteratively reweighted least squares (IRLS) algorithm follows from
a quadratic approximation of the log-likelihood. We derive this approximation
here and derive the iterative algorithm in the next section. Based on the second
order Taylor expansion of the log-likelihood,
ℓ(η) ≈ ℓ(η(s)) + (η − η(s))T ℓ′(η(s)) + 1
2
(η − η(s))ℓ′′(η(s))(η − η(s)) (A.15)
= (η − η(s))Tv − 1
2
(η − η(s))TW (η − η(s)) (A.16)
= −1
2
(η − η(s) − vW−1)TW(η − η(s) − vW−1) (A.17)
= −1
2
(y˜ − η)TW(y˜ − η) (A.18)
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where the working response, y˜ = η(s)+vW−1, is a function of the linear predic-
tor at the sth iteration. Reparameterizing as a function of β,
ℓ(β) = −1
2
(y˜ −Xβ)TW(y˜ −Xβ) (A.19)
This is equivalent to the IRLS Fisher scoring system where the Hessian is re-
placed by its expectation [125]. In standard Fisher scoring notation, the expected
Hessian is:
E
[
∂2ℓ
∂β∂β
]
= −XTWX (A.20)
as is the case in equation (A.19). Expressed in stardard notation, the working
responses are
y˜ = g(µ) + g′(µ)(y − µ) (A.21)
where it is trivial to show this is equivalent to y˜ = η(s) + vW−1.
Details of derivation
Equation numbers and an explanation of their derivation:
(A.15) A second order approximation to ℓ(η) as in Breheny and Huang [16].
This is equivalent to the Fisher scoring algorithm of IRLS.
(A.16) Plug in v for the first derivative and −W for the Hessian and drop terms
that don’t depend on η (i.e. drop ℓ(η(s)))
(A.17) Complete the square as in Breheny and Huang [16]: In general, ax2+bx+
c = a(x − h)2 + k where h = − b
2a
and k = c − b2
4a
In this case, a = −1
2
W, b = v,
c = 0 and x = (Xβ − η(s)) so h = vW−1 and k can be dropped since it does not
depend on β.
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(A.18) Plug in y˜ = η(s) + vW−1
A.1.3 Estimation in unpenalized generalized linear models
While standard IRLS methods update all regression parameters in a single step,
here we derive a coordinate-wise gradient descent algorithm for estimating β in
an unpenalized GLM and extend it to the penalized case in the next section. Fol-
lowing Breheny and Huang [17], Friedman et al. [47, 48], consider the quadratic
approximation to the log-likelihood and construct a coordinate-wise Newton-
Raphson update of βj using the first and second derivatives.
ℓ(β) = −1
2
(y˜ −Xβ)TW(y˜ −Xβ) (A.22)
= −1
2
(y˜ −
∑
k 6=j
xkβk − xjβj)TW(y˜ −
∑
k 6=j
xkβk − xjβj) (A.23)
∂ℓ
∂βj
= (y˜ −
∑
k 6=j
xkβk − xjβj)TWxj (A.24)
= (y˜ −
∑
k 6=j
xkβk)
TWxj − βjxTjWxj (A.25)
= (xjβ
(s)
j + v)
TWxj − βjxTjWxj (A.26)
= β
(s)
j x
T
jWxj + v
TWxj − βjxTjWxj (A.27)
∂2ℓ
∂βj∂βj
= −xTjWxj (A.28)
The coordinate-wise update follows from the standard Newton-Raphson up-
date formula.
β
(s+1)
j = β
(s)
j −
ℓ′(β
(s)
j )
ℓ′′(β
(s)
j )
(A.29)
= β
(s)
j +
β
(s)
j x
T
jWxj + v
TWxj − β(s)j xTjWxj
xTjWxj
(A.30)
= β
(s)
j +
vTWxj
xTjWxj
(A.31)
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This gives the coordinate-wise update:
β
(s+1)
j =
β
(s)
j x
T
jWxj + v
TWxj
xTjWxj
(A.32)
A.1.4 Estimation in penalized generalized linear models
Following the derivation from the previous section, now consider a penalized
GLM where a penalty term is added to the standard log-likelihood of a GLM.
Specifically, consider a GLM log-likelihood with an arbitrary penalty p(.) on the
magnitute of βj :
ℓ(β) = −1
2
(y˜ −Xβ)TW(y˜ −Xβ)−
∑
j
p(βj) (A.33)
The coordinate-wise Newton-Raphson update is:
β
(s+1)
j = β
(s)
j −
ℓ′(β
(s)
j )− p′(β(s)j )
ℓ′′(β
(s)
j )− p′′(β(s)j )
(A.34)
= β
(s)
j +
vTWxj − p′(β(s)j )
xTjWxj + p
′′(β
(s)
j )
(A.35)
While this update considers p(.) in general, specific penalty functions are con-
sidered below.
Least Absolute Shrinkage and Selection Operator (LASSO)
Proposed by Tibshirani [187]. Consider the penalty function and its derivatives.
pLASSO(βj) = λ|βj| (A.36)
p′LASSO(βj) = λsign(βj) (A.37)
p′′LASSO(βj) = 0 (A.38)
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The coordinate-wise Newton-Raphson update is
β
(s+1)
j = β
(s)
j +
vTWxj − λsign(β(s)j )
xTjWxj
(A.39)
=
β
(s)
j x
T
jWxj + v
TWxj − λsign(β(s)j )
xTjWxj
(A.40)
=
d− λsign(d)
xTjWxj
(A.41)
where d = β
(s)
j x
T
jWxj + v
TWxj .
Thus |d| > λ yields (|d| − λ)sign(d) but |d| ≤ λ yields an update of 0 so that
β
(s+1)
j is set to zero if the derivative of the lasso penalty exceeds the unpenalized
update. This can be stated using the soft-thresholding function of Donoho and
Johnstone [35] (see Tibshirani [187] for orginal use in lasso regression):
βj =
S(d, λ)
xTjWxj
(A.42)
where
S(d, λ) =


d− λ d > 0 and λ < |d|
d+ λ d < 0 and λ < |d|
0 λ ≥ |d|
(A.43)
Note the similar application of the soft-thresholding function by Friedman et al.
[47, 48], Schifano et al. [166], Wu et al. [209], Wu and Lange [210]. Also note that
ℓ(β) is not differentiable when βj = 0, but a directional derivative still exists and
has magnitude λ [210]. Therefore the updates above are valid even if βj = 0.
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Minimax concave penalty (MCP)
Proposed by Zhang [221]. Consider the penalty function and its derivatives.
pMCP(βj) =


λ|βj| − β
2
j
2a
|βj| ≤ aλ
1
2
aλ2 |βj| > aλ
(A.44)
p′MCP(βj) =


λsign(β
(s)
j )− βja |βj| ≤ aλ
0 |βj| > aλ
(A.45)
p′′MCP(βj) =


− 1
a
|βj| ≤ aλ
0 |βj| > aλ
(A.46)
The coordinate-wise Newton-Raphson update is
β
(s+1)
j = β
(s)
j +
vTWxj − λsign(β(s)j ) +
β
(s)
j
a
xTj Wxj − 1a
(A.47)
=
β
(s)
j (x
T
jWxj − 1a) + vTWxj − λsign(β(s)j ) +
β
(s)
j
a
xTjWxj − 1a
(A.48)
=
S(d, λ)
xTjWxj − 1a
(A.49)
β
(s+1)
j =


S(d,λ)
xT
j
Wxj−
1
a
d ≤ aλxTjWxj
d
xT
j
Wxj
d > aλxTjWxj
(A.50)
Notice the bounds change in (A.50) to adjust for the scale of the second deriva-
tive according to Breheny and Huang [16, 17].
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Negative exponential gamma (NEG)
Proposed by Griffin and Brown [54, 55], but see Hoggart et al. [72] for more
details. Consider the penalty function and its derivatives.
pNEG(β) = − β
2
4γ2
− logD−2λ−1( |β|
γ
) (A.51)
p′NEG(β) = sign(β)
2λ+ 1
γ
D−2λ−2(
|β|
γ
)
D−2λ−1(
|β|
γ
)
(A.52)
p′′NEG(βj) = −
4
γ
[
(λ+ 1)(λ+
1
2
)
D−2λ−3(
|β|
γ
)
D−2λ−1(
|β|
γ
)
−
[
(λ+
1
2
)
D−2λ−2(
|β|
γ
)
D−2λ−1(
|β|
γ
)
]2]
(A.53)
D.(.) denotes the parabolic cylinder function [139]. We use a Fortran implenta-
tion of this function available in the SciPy library: http://projects.scipy.
org/scipy/export/6949/trunk/scipy/special/specfun/specfun.f
The coordinate-wise Newton-Raphson update is
βj = β
(s)
j +
vTWxj − p′NEG(β(s)j )
xTjWxj − p′′NEG(β(s)j )
(A.54)
and cannot be simplified due to the complicated form for the penalty.
LOG penalty
Proposed by Mazumder et al. [124]. Consider the penalty function and its
derivatives.
pLOG(βj) = λ
log(1 + |βj|/ǫ)
log(1 + 1/ǫ)
(A.55)
p′LOG(βj) =
λ
log(1 + 1/ǫ)
sign(βj)/ǫ
1 + |βj|/ǫ (A.56)
p′′LOG(βj) =
−λ
log(1 + 1/ǫ)
[sign(βj)/ǫ]
2
[1 + |βj|/ǫ]2
(A.57)
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The coordinate-wise Newton-Raphson update is
βj = β
(s)
j +
vTWxj − p′LOG(β(s)j )
xTjWxj − p′′LOG(β(s)j )
(A.58)
A.1.5 Updating quantities during iteration of algorithm
When βj is updated, v andW must be updated accordingly. In general, initial-
ize η as:
η(0) = Xβ(0). (A.59)
At each iteration where β
(s+1)
j 6= β(s)j , update η, v andW according to
η(s+1) = η(s) + xj
(
β
(s+1)
j − β(s)j
)
(A.60)
µ = g−1(η) (A.61)
v = y − µ (A.62)
W = 1/g′(µ) (A.63)
A.1.6 Convergence and a minorize-maximization algorithm
It is widely known that Newton-Raphson algorithms are not guaranteed to con-
verge unless the objective function is quadratic. Since we are using a quadratic
approximation of the objective function, the Fisher scoring system is not guar-
anteed to converge. The Fisher scoring method of IRLS tends to converge in
practice in overdetermined systems, yet the highly underdetermined systems
addressed here may be problematic. In fact, Hoggart et al. [72] and Genkin et al.
[51] replace the Hessian with an upper bound so that the system always con-
verges. Intuitively, this upper bound prevents taking steps that are too large
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and actually decrease the value of the objective function.
These examples are generalized by Hunter et al. [75], who describe a very
general method to construct a surrogate function that minorizes the objective
function. They demonstrate that iteratively maximizing the surrogate and con-
structing a new surrogate can guarantee convergence on non-quadratic surfaces
without expensive backtracking checks that evaluate the log-likelihood at each
update. One simple method to construct a surrogate function which minorizes
the objective function is to replace the Hessian with an upper bound. This effec-
tively decreases the step size so that the value of the objective function always
increases and a backtracking step is not needed.
Convergence can therefore be guaranteed if the matrixW used in the quadratic
approximation is replaced by an upper bound. Consider the upper bound on
the Hessian for the following links:
• linear: the system is exactly quadratic so thatW = diag(1) and no bound
is needed.
• logistic:W = diag(µ(1− µ)) so thatWupper = 14diag(1)
since µi ∈ [0, 1] and max(µi(1− µi)) = .25
(see example in Hunter et al. [75])
For logistic regression, replacingWwithWupper to guarantees convergence and
increases the speed of each update since it avoids calculating µ and µ(1− µ).
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A.1.7 Implementation
Our implementation of these penalized likelihood methods is especially effi-
cient since we 1) store the dataset to mimimize access time for each feature, 2)
use highly optimized Intel R© Math Kernel Library R© for linear algebra operations
and 3) evaluate multiple modes of the nonconvex posterior surface in parallel
using OpenMP R©. This very fast implementation allowed efficient exploration
of the two-dimensional space of tuning parameters for MCP, LOG and NEG
penalties using the relaxation method of Mazumder et al. [124].
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A.2 Running HyperLasso
We ran hyperLasso following the instructions on the program website (http:
//www.ebi.ac.uk/projects/BARGEN/) that suggested the following flags:
-shape 0.1 -lambda 50 -std
Setting the lambda values based on asymptotic arguments described by Hog-
gart et al. [72] either produced very few markers with non-zero coefficients or
caused the program to crash.
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Figure A.1: Assessing p-value cutoff in two-step forward regression. Plots
show − log10 p-values from a single marker analysis (x-axis)
compared to the change in − log10 p-values from a conditional
regression analysis where markers passing the Bonferroni cut-
off are included as covariates (y-axis). Markers passing the
Bonferroni cutoff in the first step (red points) are necessary
omitted from being tested in the second step, and are con-
sidered to have no change in p-value. Markers with a large
enough increase in − log10 p-value in the second step to cross
the second Bonferroni cutoff (blue dashed line) are indicated
by green points. The p-value cutoff of 0.01 (i.e. a − log10 p-
value of 2) is indicated by the grey dashed line. Results are
shown for 10 replicate simulations each of (a) 1000, (b) 2000,
and (c) 5000 samples with 500K markers, heritability of 30, 40,
50 or 60% and 30, 40, 50, 70 or 100 simulatedmarkers with true
nonzero coefficients. This corresponds to 200 simulations and
1× 108 p-values for each sample size. The results indicate that
in a forward regression, which approximates penalized multi-
ple regression [37, 63], markers with small − log10 p-values in
the first step have a very low probability of being significant in
the second step. Therefore, using a p-value cutoff of 0.01 from
a marginal regression retains almost all relevant variables un-
der biologically motivated simulation conditions.
(a) 1000 samples
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(b) 2000 samples
(c) 5000 samples
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Figure A.2: Effect of pre-screening on performance of PUMA. (a) 100
replicate simulations with 500K markers, 50 causal markers,
heritability of 50% and 1000 or 2000 individuals using Lasso
and MCP methods show that using a pre-screening p-value
cutoff of 1, 0.10 and 0.01 has no noticeable effect of perfor-
mance of PUMA. Note that the performance was so similar
for all cutoffs that the curves are overlapping. (b) Running
times for simulations in (a) show that pre-screening substan-
tually reduces computational time. We note that simulations
with 5000 individuals were not possible due to the very high
memory requirements of running PUMA without prescreen-
ing.
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(b) Run times for each prescreening cutoff
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Figure A.3: Simulation results showing power for our PMRmethods, cur-
rent PMR methods, an approximate Bayesian method, single
marker analysis and conditional regressionmethods at an FDR
of 5% as a function of sample size as in Figure 2.3c in the main
text. Results are shown for a range of total heritabilities and
number of susceptibility loci.
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Figure A.4: Simulation results showing power for our PMRmethods, cur-
rent PMR methods, an approximate Bayesian method, single
marker analysis and conditional regressionmethods at an FDR
of 5% as a function of the number of susceptibility loci. Results
are shown for a range of sample sizes and total heritabilities.
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Figure A.5: Simulation results showing power a sample size of 1000
for our PMR methods, current PMR methods, an approxi-
mate Bayesianmethod, singlemarker analysis and conditional
regression methods at an FDR of 5% as a function of the
marginal heritability of each causal marker as in Figure 2.3a
in the main text. Results are shown for a range of total heri-
tabilities and number of causal markers.
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Figure A.6: Simulation results showing power a sample size of 2000
for our PMR methods, current PMR methods, an approxi-
mate Bayesianmethod, singlemarker analysis and conditional
regression methods at an FDR of 5% as a function of the
marginal heritability of each causal marker as in Figure 2.3a
in the main text. Results are shown for a range of total heri-
tabilities and number of causal markers..
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Figure A.7: Simulation results showing power a sample size of 5000
for our PMR methods, current PMR methods, an approxi-
mate Bayesianmethod, singlemarker analysis and conditional
regression methods at an FDR of 5% as a function of the
marginal heritability of each causal marker as in Figure 2.3a
in the main text. Results are shown for a range of total heri-
tabilities and number of causal markers.
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Figure A.8: Simulation results showing precision-recall curves for a sam-
ple size of 1000. Results are shown for a range of total heri-
tabilities and number of causal markers. Solid colors for pML
methods indicate results using our method for assessing sig-
nificance in the presence of correlated markers, while dashes
indicate the significance method of Wu et al. [209] and perm-
MCP [9]. This figures is analogous to Figure 2.3b in the main
text.
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Figure A.9: Simulation results showing precision-recall curves for a sam-
ple size of 2000. Results are shown for a range of total heri-
tabilities and number of causal markers. Solid colors for pML
methods indicate results using our method for assessing sig-
nificance in the presence of correlated markers, while dashes
indicate the significance method of Wu et al. [209] and perm-
MCP [9]. This figures is analogous to Figure 2.3b in the main
text.
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Figure A.10: Simulation results showing precision-recall curves for a sam-
ple size of 5000. Results are shown for a range of total heri-
tabilities and number of causal markers. Solid colors for pML
methods indicate results using our method for assessing sig-
nificance in the presence of correlated markers, while dashes
indicate the significance method of Wu et al. [209] and perm-
MCP [9]. This figures is analogous to Figure 2.3b in the main
text.
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Figure A.11: Precision-Recall curves for perm-MCP for multiple values
of eFPR and pre-screening p-value cutoff. Simulations for
5000 samples, 20 causal markers and heritability of 50% using
eFPR values (1× 10−3,1× 10−4,1× 10−5,1× 10−6,1× 10−7)
and pre-screening cutoff values (0.1, 0.01, 0.001) indicated in
the legend. Results from single marker analysis andMCP-2D
are shown for comparison.
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Figure A.12: Quantile-Quantile plots for each disease and method. Plots
are shown for a) Crohn’s disease, b) Rheumatoid arthri-
tis and c) Type 1 diabetes. Results from a standard single
marker analysis of each disease are shown in grey and are the
same in all plots for a given disease. Results from including
the subset of significantly associated markers identified by
each pML method as covariates in a single marker analysis
of remaining markers is shown in black, where the relevant
method is indicated above each plot. Results from replacing
the p-values from this latter analysis with p-values from the
PMR method for the relevant markers with nonzero coeffi-
cients are shown in color. The genomic inflation values for
are shown in the upper left of each plot. Note that the NEG
method failed for the type 1 diabetes dataset, so no plot is
shown.
(a) Crohn’s disease
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(b) Rheumatoid arthritis
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(c) Type 1 diabetes
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Figure A.13: Manhattan plot showing results of single marker analysis for
three disease datasets from our re-analysis. Shown are− log10
p-values where large values are truncated at 20. Markers
with − log10 p-values > 6 are colored green.
(a) Crohn’s disease
(b) Rheumatoid arthritis
(c) Type 1 diabetes
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Figure A.14: Genome-wide plot of associations identified by analyzing the
WTCCC data for a) Crohn’s disease, b) rheumatoid arthri-
tis and c) type 1 diabetes using PMR methods, conditional
regression, and single marker analysis. External associations
from independent datasets (which do not include WTCCC
data) and non-independent datasets (which include WTCCC
data) of the same disease are indicated with pink boxes and
diamonds, respectively. Markers that are considered associa-
tions only when the p-value threshold for the single marker
analysis is relaxed to match the same number of associations
(with hits in the MHC region excluded) as the union of all
PMR methods are indicated with black circles. Arrows indi-
cate novel associations that are biologically interpretable.
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(b) Rheumatoid arthritis
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(c) Type 1 diabetes
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Figure A.15: Local manhattan plots of hits replicated from an independent
study of Crohn’s disease
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Figure A.16: Local manhattan plots of hits replicated from an independent
study of rheumatoid arthritis
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Figure A.17: Local manhattan plots of hits replicated from an independent
study of type 1 diabetes
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Figure A.18: Local manhattan plots hits replicated from a non-
independent study of Crohn’s disease
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Figure A.19: Local manhattan plots of hits replicated from a non-
independent study of type 1 diabetes
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Figure A.20: Local manhattan plots of biologically relevant hits for
Crohn’s disease
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Figure A.21: Local manhattan plots of biologically relevant hits for
rheumatoid arthritis
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Figure A.22: Local manhattan plots of biologically relevant hits for type 1
diabetes
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Table A.5: For each method, the number of associations in this re-analysis
that replicate associations identified in a) independent (not
including WTCC data) and b) non-independent (including
WTCC data) datasets, where the number of markers considered
as ‘hits’ is set to be equal across methods. For each method the
number of hits is set to a given value and the number of replica-
tions is reported. Numbers in parentheses indicate the number
of hits that are distinct from those found by the single marker
analysis.
a) Independent studies
# considered Method
as hits SMA Conditional test VBAY Lasso Adaptive Lasso 2D-MCP LOG NEG 1D-MCP
CD 5 4 4 (0) 4 (0) 4 (0) 4 (0) 4 (0) 4 (0) 4 (0) 4 (0)
10 6 6 (0) 4 (0) 5 (0) 4 (0) 4 (0) 5 (0) 5 (0) 5 (0)
15 6 6 (0) 4 (0) 5 (0) 5 (0) 4 (0) 5 (0) 5 (0) 5 (0)
25 7 6 (0) 5 (0) 5 (0) 5 (0) 5 (0) 6 (0) 6 (0) 6 (0)
30 7 6 (0) 5 (0) 5 (0) 6 (0) 6 (0) 6 (0) 6 (0) 6 (0)
RA 5 2 2 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
10 2 2 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
15 2 2 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
25 2 2 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
30 2 2 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
T1D 5 3 3 (0) 3 (0) 3 (0) 2 (0) 3 (0) 2 (0) 0 3 (0)
10 4 4 (0) 4 (1) 4 (1) 3 (1) 3 (0) 4 (1) 0 4 (1)
15 5 4 (0) 4 (0) 4 (0) 3 (0) 3 (0) 5 (0) 0 4 (0)
25 5 5 (0) 5 (0) 5 (0) 4 (0) 4 (0) 5 (0) 0 5 (0)
30 5 5 (0) 5 (0) 5 (0) 4 (0) 5 (0) 5 (0) 0 5 (0)
b) Non-independent studies
# considered Method
as hits SMA Conditional test VBAY Lasso Adaptive Lasso 2D-MCP LOG NEG 1-MCP
CD 5 5 5 (0) 5 (0) 5 (0) 5 (0) 5 (0) 5 (0) 5 (0) 5 (0)
10 9 9 (0) 6 (0) 7 (1) 7 (1) 6 (0) 7 (1) 8 (2) 8 (2)
15 11 11 (0) 8 (0) 8 (0) 8 (0) 7 (1) 8 (0) 11 (2) 11 (4)
25 15 13 (0) 12 (2) 13 (3) 12 (2) 11 (1) 15 (3) 14 (2) 16 (4)
30 16 14 (0) 14 (3) 14 (3) 16 (3) 12 (0) 16 (4) 16 (4) 17 (4)
RA 5 3 3 (1) 2 (1) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
10 3 4 (1) 2 (1) 2 (1) 2 (1) 1 (0) 1 (0) 2 (1) 2 (1)
15 4 4 (1) 2 (1) 2 (0) 3 (1) 1 (0) 3 (1) 2 (0) 3 (1)
25 6 5 (0) 3 (0) 3 (0) 3 (0) 2 (0) 3 (0) 4 (0) 3 (0)
30 6 5 (0) 3 (0) 4 (0) 4 (0) 2 (0) 3 (0) 4 (0) 3 (0)
T1D 5 3 3 (0) 3 (0) 3 (0) 2 (0) 3 (0) 2 (0) 0 3 (0)
10 4 4 (0) 4 (1) 4 (1) 3 (1) 4 (1) 4 (1) 0 4 (1)
15 6 5 (0) 5 (1) 4 (0) 3 (0) 4 (1) 5 (0) 0 4 (0)
25 7 7 (0) 7 (1) 6 (0) 7 (2) 5 (1) 6 (1) 0 5 (0)
30 8 7 (0) 8 (1) 6 (0) 7 (2) 6 (1) 7 (2) 0 6 (1)
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A.3 Effective degrees of freedom for the linear mixed model
Show that tr(H) =
∑
i
s2i
s2
i
+δ
, letting δ = σ
2
e
σ2a
and s2i be the i
th eigen-value ofK. The
derivation follows from standard properties of matrix algebra and orthonormal
matrices in the eigen-decomposition.
H = K(K+ Iδ)−1
= K(US2UT +UUT δ)−1
= K
[
U(S2 + Iδ)UT
]−1
= KU(S2 + Iδ)−1UT
= US2UTU(S2 + Iδ)−1UT
= US2(S2 + Iδ)−1UT
tr(H) = tr[US2(S2 + Iδ)−1UT ]
= tr[S2(S2 + Iδ)−1UTU]
= tr[S2(S2 + Iδ)−1]
=
∑
i
s2i
s2i + δ
We note that evaluating dfe for the low rank linear mixed model has the same
form since no assumption of positivity was made for the values of s2i .
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Figure A.23: Manhattan plots for HDL cholesterol in Europeans from the
Multi-Ethnic Study of Atherosclerosis (MESA) using Plink,
EMMAX, GEMMA, fastlmm and our low rank linear mixed
model sorting by degrees of freedom from fitting each prin-
cipal component individually (LRLMM-DF).
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